document incorporate reference document proxy statement annual meeting shareholder hold file iii security exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item b unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature table content item business merck co inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company recently sell certain business healthcare service segment process divest remain business company continue look investment opportunity area health care approach investment shift venture capital investment party oppose whollyowne business alliance segment primarily include activity company relationship astrazeneca lp relate sale nexium prilosec conclude company incorporate new jersey product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner plan spinoff womens health legacy brand biosimilar new company february merck announce intention spinoff spinoff product womens health trust legacy brand biosimilar business new yettobename independent publicly trade company newco distribution newco publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose legacy brand include transaction consist dermatology pain respiratory select cardiovascular product include zetia vytorin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan newco development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete half subject market certain condition risk factor risk relate propose spinoff newco table content product sale total company sale include sale company pharmaceutical product sale animal health product follow million total sale pharmaceutical keytruda januviajanumet gardasilgardasil proquadmmr iivarivax bridion isentressisentress hd pneumovax nuvare zetiavytorin simponi animal health livestock companion animal revenue revenue primarily comprise healthcare service segment revenue thirdparty manufacture sale miscellaneous corporate revenue include revenue hedging activity pharmaceutical pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office certain product company franchise follow oncology keytruda pembrolizumab company antipd program death receptor therapy monotherapy treatment certain patient melanoma nonsmallcell lung cancer nsclc smallcell lung cancer sclc head neck squamous cell carcinoma hnscc classical hodgkin lymphoma chl primary mediastinal large bcell lymphoma pmbcl urothelial carcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer gastric gastroesophageal junction adenocarcinoma esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma keytruda treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination axitinib renal cell carcinoma combination lenvatinib endometrial carcinoma emend aprepitant prevention chemotherapyinduce postoperative nausea vomit addition company recognize alliance revenue relate sale lynparza olaparib oral poly adpribose polymerase parp inhibitor certain type advance ovarian breast pancreatic cancer lenvima lenvatinib certain type thyroid cancer hepatocellular carcinoma combination everolimus certain patient renal cell carcinoma combination keytruda certain patient endometrial carcinoma vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child vaqta hepatitis vaccine inactivated indicate prevention disease cause hepatitis virus person month age old table content hospital acute care bridion sugammadex injection medication reversal type neuromuscular block agent surgery noxafil posaconazole prevention invasive fungal infection primaxin imipenem cilastatin sodium antibacterial product invanz ertapenem sodium treatment certain infection cubicin daptomycin injection iv antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism cancida caspofungin acetate antifungal product prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipient r allogeneic hematopoietic stem cell transplant immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease remicade infliximab treatment inflammatory disease company market europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicate treatment insomnia characterize difficulty sleep onset andor sleep maintenance virology isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection zepati elbasvir grazoprevir treatment adult patient chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient population cardiovascular zetia ezetimibe market ezetrol country outside united states vytorin ezetimibesimvastatin market inegy outside united states atozet ezetimibe atorvastatin market outside united states rosuzet ezetimibe rosuvastatin market outside united states cholesterol modifying medicine adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete women health nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshape subdermal contraceptive implant animal health animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine health management solution service extensive suite digitally connect identification traceability monitoring product principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine exzolt systemic treatment poultry red mite infestation slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solution animal identification monitor traceability table content companion animal product bravecto fluralaner line oral topical parasitic control product dog cat week nobivac vaccine line flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabete mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line horse scalibor deltamethrinexspot protect bite flea tick mosquitoe sandflies discussion sale company product item management discussion analysis financial condition result operation product approval set forth summary significant product approval receive company product date approval food drug administration fda approve ervebo prevention disease cause december zaire ebolavirus individual year age old ervebo european commission ec grant conditional marketing authorization ervebo active november immunization individual year age old protect ebola virus disease cause zaire ebola virus japanese ministry health labour welfare mhlw approve keytruda new firstline december indication advanced renal cell carcinoma rcc recurrent distant metastatic head neck cancer ec approve new regimen keytruda firstline treatment metastatic unresectable recurrent november head neck squamous cell carcinoma hnscc china national medical products administration nmpa approve keytruda firstline treatment metastatic squamous nonsmall cell lung cancer nsclc november combination chemotherapy keytruda nmpa approve keytruda monotherapy firstline treatment certain patient advance nsclc october tumor express pdl fda approve keytruda plus lenvima combination treatment patient certain type endometrial september carcinoma september ec approve keytruda combination axitinib firstline treatment patient advance rcc fda approve keytruda recurrent locally advanced metastatic squamous cell carcinoma july esophagus patient tumor express pdl combine positive score cp cp disease progression prior line systemic therapy table content june fda approve keytruda monotherapy patient metastatic smallcell lung cancer sclc disease progression platinumbase chemotherapy prior line therapy fda approve indication keytruda firstline treatment patient metastatic june unresectable recurrent hnscc monotherapy patient tumor express pdl cp combination platinum fluorouracil regardless pdl expression april fda approve keytruda combination axitinib firstline treatment patient advance rcc fda approve expand label keytruda monotherapy firstline treatment patient stage iii nsclc candidate surgical resection definitive chemoradiation metastatic april nsclc tumor express pdl tumor proportion score tps determine fda approve test epidermal growth factor receptor egfr anaplastic lymphoma kinase positive alk genomic tumor aberration keytruda april ec approve new extended dose schedule keytruda approve monotherapy indication nmpa approve keytruda firstline treatment metastatic nonsquamous nsclc combination april chemotherapy march ec approve keytruda combination chemotherapy firstline treatment adult metastatic squamous nsclc february fda approve keytruda adjuvant treatment patient melanoma involvement lymph node follow complete resection mhlw approve keytruda indication include expand use advanced nsclc january melanoma new indication advance microsatellite instabilityhigh tumor fda approve lynparza firstline maintenance therapy patient germline brcamutate december gbrcam metastatic pancreatic cancer disease progress week line platinumbase chemotherapy regiman december nmpa approve lynparza firstline maintenance therapy brcam advance ovarian cancer july ec approve lynparza monotherapy maintenance treatment adult patient advance brcam highgrade epithelial ovarian fallopian tube primary peritoneal cancer lynparza mhlw approve lynparza firstline maintenance therapy patient brcam advanced ovarian june cancer june ec approve lynparza use firstline maintenance therapy patient brcam advanced ovarian cancer april ec approve lynparza treatment gbrcam hernegative advanced breast cancer fda approve supplemental new drug application snda pifeltro doravirine combination pifeltro delstrigo september antiretroviral agent delstrigo doravirine lamivudine tenofovir disoproxil fumarate complete regimen use appropriate adult hiv infection virologically suppress stable antiretroviral regimen table content fda approve recarbrio imipenem cilastatin relebactam treatment adult complicated recarbrio july urinary tract complicate intraabdominal bacterial infection limit alternative treatment option available ec approve zerbaxa treatment adult hospitalacquire pneumonia include ventilator august associate pneumonia combination antibacterial agent active grampositive zerbaxa pathogen know suspect contribute infectious process fda approve zerbaxa g dose treatment patient year old hospitalacquire june bacterial pneumonia ventilatorassociate bacterial pneumonia habpvabp bravecto november fda approve bravecto plus topical solution cat indicate external internal parasite infestation july merck astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company wellpositione compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance license arrangement collaboration refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient table content backdrop united states enact major health care reform legislation patient protection affordable care act aca insurance market reform advanced state federal insurance exchange launch respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal b drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap ie socalle donut hole result balanced budget act effective beginning point service discount increase point service discount coverage gap addition point service discount extend biosimilar product merck record reduction revenue approximately million million million respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion decrease billion expect remain fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost sell general administrative expense respectively annual health care reform fee february center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs impact change result issuance rule material merck time company await guidance cms aspect rule defer later implementation include definition constitute product line extension delay participation territory medicaid drug rebate program april company evaluate financial impact element effective significant uncertainty future aca particular health care law general united states company participate debate monitoring propose change affect business company unable predict likelihood change aca depend nature repeal replacement aca action material adverse effect company business cash flow result operation financial condition prospect number state pass pharmaceutical price cost transparency law law typically require manufacturer report certain product price information financial datum state law require manufacturer provide advance notification price increase company expect state continue focus pharmaceutical price transparency focus continue exert pressure product pricing company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care organization federal state exchange institutional governmental purchasers ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control addition congress andor administration consider proposal allow international reference price certain condition importation medicine country administration recently propose draft rule allow importation certain lowercost prescription drug canada rule finalize propose state certain nonfederal governmental entity able submit importation program proposal fda review authorization twoyear program opportunity extend year public comment period propose rule expire march follow comment period fda review finalize table content proposal state party submit plan comply federal rule propose rule adopt likely time state party actually implement importation plan october administration issue advance notice propose rulemaking implement international pricing index ipi model united states product cover medicare b proposal reduce medicare b payment drug base market basket international price allow private sector vendor negotiate price drug title drug compete physician hospital business change physician reimbursement medicare b current model eliminate buy bill system instead pay physician base flat fee approximate revenue currently receive drug public comment ipi proposal accept late unclear agency issue propose rule ipi model adoption propose rule material adverse effect company business result operation financial condition remain uncertain proposal include future federal legislative proposal directly indirectly affect company private sector consolidation integration health care provider major factor competitive marketplace pharmaceutical product health plan pharmacy benefit manager consolidate few large entity enhance purchasing strength importance private thirdparty insurer government increasingly employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain placement unfavorable pricing adversely impact revenue addition formulary tier copay differential private health insurance company selfinsure employer raise co payment require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product generic product available require patient fail generic product permit access brand medicine management tool treatment area payer take position multiple brand product therapeutically comparable payer market concentrate drug available generic form pharmaceutical company face great pricing pressure private thirdparty payer order provide information company pricing practice company annually post website pricing transparency report united states report provide company average annual list price net price increase average discount company portfolio date company gross sale reduce approximately result rebate discount return effort health care cost containment remain intense european country company face competitive pricing pressure result generic biosimilar drug addition majority country europe attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company drug guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine occur occur furthermore government order repricing specific product determine use product exceed certain threshold define applicable repricing rule pursuant rule japanese government reduce price keytruda effective february additionally keytruda subject significant price reduction april provision japanese pricing rule company business china grow rapidly past year importance china company overall pharmaceutical vaccine business increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company current inline product absence trade impediment adverse pricing control recent year chinese government introduce implement number structural reform accelerate shift innovative product reduce cost multiple new policy introduce government improve access new innovation reduce table content complexity regulatory filing accelerate review approval process lead significant increase number new product approve year additionally chinese government update national reimbursement drug list time year mechanism drug add list evolve inclusion require price negotiation impact outlook market select brand drug add pathway direct inclusion price negotiation price negotiation price reduction approximately average require inclusion pricing pressure exist china health care reform increase pressure acceleration generic substitution volume base procurement vbp government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction expansion vbp program remains see company focus emerge market addition china continue government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market include china certain market outside united states implement cost management strategy health technology assessment hta example include uk france germany ireland italy sweden hta process procedure accord assessment public health impact therapeutic impact economic social impact use give medicinal product national health care system individual country conduct hta generally focus clinical efficacy effectiveness safety cost costeffectiveness individual medicinal product potential implication health care system element medicinal product compare treatment option available market outcome hta influence pricing reimbursement status grant medicinal product regulatory authority individual european union eu member states negative hta company product lead recognize hta body undermine companys ability obtain reimbursement product eu member state negative assessment issue eu member states hta procedure require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement united states htas government private payer price market access challenge condition emerge market country affect company effort continue grow market include potential political instability change trade sanction embargo significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe wellpositione respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement table content particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation accelerate regulatory review process medicine designation fda undertake effort bring generic competition market efficiently timely manner eu adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard eu supplemented implement additional regulation eu member states particular eu regulator approve product subject number postauthorization condition example typical postauthorization commitment include additional pharmacovigilance conduct clinical trial establishment patient registry physician patient education control distribution prescribing arrangement noncompliance postauthorization condition pharmacovigilance obligation lead regulatory action include variation suspension withdrawal marketing authorization enforcement regulatory action include imposition financial penalty company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access medicine vaccine quality health care world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition innovative social investment include philanthropic program impact investing merck help strengthen health system build capacity particularly underresourced community merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccines merck launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent grantmaking organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include eu general data protection regulation go effect impose penalty global revenue california consumer privacy act effective january additional law regulation enact united states europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk certify compliant approve asia pacific economic cooperation crossborder privacy rule system euus swissus privacy shield program bind corporate rule eu distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy table content benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademarks license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term period patent product regulatory review fda eu provide additional month pediatric market exclusivity attach product supplementary protection certificate spc japan provide additional term pediatric study attach market exclusivity unrelated patent term patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection united states eu japan china include potential patent term extension pte spc indicate follow market product table content product year expiration year expiration eu year expiration japan year expiration china emend injection expire na januvia janumet na janumet xr na na isentress simponi na na na lenvima pende pte patent spc adempas bridion pende pte nexplanon device device market bravecto pende pte patent spc gardasil expire na gardasil patent spc na keytruda patent spc lynparza pende pte patent spcs zerbaxa patent spc pende pte na belsomra na na prevymis pende pte patent spc na steglatro pende pte patent spc na steglujan pende pte patent spc na segluromet pende pte patent spc na delstrigo pende pte patent spc na na pifeltro pende pte patent spc na na recarbrio pende pte na na na notecompound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability na currently market approval eu date represent expiration date follow country france germany italy spain united kingdom major eu market spc application file grant major eu markets patent expiry date spc expiry date list pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date eligible month pediatric exclusivity company marketing right japan china expiration distribution agreement janssen pharmaceuticals inc global strategic oncology collaboration eisai commercialize worldwide collaboration bayer ag global strategic oncology collaboration astrazeneca commercialize promote worldwide japan collaboration pfizer inc table content company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration mk gefapixant mk vericiguat v pneumoconjugate vaccine mka islatravirdoravirine develop worldwide collaboration bayer ag note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program december approximately people employ company research activity company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize table content company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit ensure externally source program remain important component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease diabete metabolic disease infectious disease neuroscience pain respiratory disease vaccine development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase ab trial design twostage trial design consist phase proofofconcept stage phase b doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study eg multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act v pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda table content order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review addition generate antibiotic incentive act fda grant qualified infectious disease product qidp status antibacterial antifungal drug intend treat life threatening infection include cause antibiotic antifungal resistant pathogen novel emerge infectious pathogen qualify pathogen qidp designation offer certain incentive development qualify drug include priority review nda file eligibility fast track designation fiveyear extension applicable exclusivity provision food drug cosmetic act primary method company use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state outside united states eu company submit marketing application national regulatory authority example ministry health labour welfare japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia national medical products administration china country separate independent review process timeline market approval time long regulatory authority require approval major market united states eu issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review united states internationally keytruda antipd therapy approve treatment cancer clinical development expand indication approval result broad clinical development program currently consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nonsmallcell lung ovarian pmbcl prostate renal smallcell lung triplenegative breast urothelial currently phase clinical development trial plan cancer keytruda review eu monotherapy firstline treatment patient stage iii nsclc candidate surgical resection definitive chemoradiation metastatic nsclc tumor express pdl tps egfr alk genomic tumor aberration base result phase keynote trial table content keytruda review japan monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma base result pivotal phase keynote trial keytruda review japan monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma base result phase keynote trial merck decision withdraw type ii variation application keytruda indication eu october fda accept supplemental bla seeking use keytruda treatment patient recurrent andor metastatic cutaneous squamous cell carcinoma cscc curable surgery radiation base result keynote trial fda set pdufa date june february merck announce fda issue complete response letter crl merck supplemental bla seek update dose frequency keytruda include mg dose infuse minute everysixweek qw option multiple indication submit application base pharmacokinetic modeling simulation datum present american society clinical oncology asco annual meeting datum support ec approval mg qw dose keytruda monotherapy indication march merck review letter discuss step fda additionally keytruda receive breakthrough therapy designation fda combination neoadjuvant chemotherapy treatment highrisk earlystage triplenegative breast cancer tnbc combination enfortumab vedotin firstline set treatment patient unresectable locally advanced metastatic urothelial cancer eligible cisplatincontaine chemotherapy fda breakthrough therapy designation intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint september merck announce result pivotal neoadjuvantadjuvant phase keynote trial patient earlystage tnbc trial investigate regimen neoadjuvant keytruda plus chemotherapy follow adjuvant keytruda monotherapy keytruda regiman compare regimen neoadjuvant chemotherapy follow adjuvant placebo chemotherapyplacebo regimen interim finding present european society medical oncology esmo congress neoadjuvant phase keytruda plus chemotherapy result statistically significant increase pathological complete response pcr versus chemotherapy patient earlystage tnbc improvement see add keytruda neoadjuvant chemotherapy observe regardless pdl expression dual primary endpoint eventfreesurvival ef median followup month keytruda regimen reduce risk progression neoadjuvant phase recurrence adjuvant phase compare chemotherapyplacebo regimen merck continue discuss interim analysis datum keynote regulatory authority keytruda breast cancer clinical development program encompass internal external collaborative study february merck announce pivotal phase keynote trial investigate keytruda combination chemotherapy meet dual primary endpoint progressionfree survival pfs patient metastatic triplenegative breast cancer mtnbc tumor express pdl cp base interim analysis conduct independent datum monitor committee dmc firstline treatment keytruda combination chemotherapy nabpaclitaxel paclitaxel gemcitabinecarboplatin demonstrate statistically significant clinically meaningful improvement pfs compare chemotherapy patient base recommendation dmc trial continue change evaluate dual primary endpoint overall survival os merck announce phase keynote trial evaluate keytruda monotherapy second thirdline treatment patient metastatic tnbc meet prespecified primary endpoint superior os compare chemotherapy endpoint formally test study protocol primary endpoint os meet june merck announce result pivotal phase keynote trial evaluate keytruda monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma monotherapy arm study keytruda meet primary endpoint demonstrate noninferiority chemotherapy current standard care os patient tumor express pdl cp combination arm keynote keytruda plus chemotherapy find statistically superior os cp cps pfs cps compare chemotherapy result present american society clinical oncology asco annual meeting september fda table content approve keytruda thirdline treatment previously treat patient recurrent locally advanced metastatic gastric gastroesophageal junction cancer tumor express pdl cp determine fdaapproved test keynote potential confirmatory trial accelerate thirdline approval addition keynote additional firstline phase study merck gastric clinical program include keynote keynote keynote neoadjuvant adjuvant treatment set january merck announce phase keynote trial investigate keytruda combination chemotherapy meet dual primary endpoint pfs firstline treatment patient extensive stage sclc final analysis study improvement os patient treat keytruda combination chemotherapy compare chemotherapy os result meet statistical significance prespecified statistical plan result present upcoming medical meeting discuss regulatory authority lynparza oral parp inhibitor currently approve certain type advance ovarian breast pancreatic cancer codevelope multiple cancer type collaboration astrazeneca lynparza review eu firstline maintenance monotherapy patient gbrcam metastatic pancreatic cancer disease progress follow firstline platinumbase chemotherapy lynparza approve indication fda december base result phase polo trial decision ema expect second half january fda accept supplemental nda lynparza combination bevacizumab maintenance treatment woman advance ovarian cancer disease show complete partial response firstline treatment platinumbase chemotherapy bevacizumab base result pivotal phase paola trial pdufa date set second quarter indication review eu january fda accept priority review supplemental nda lynparza treatment patient metastatic castrationresistant prostate cancer mcrpc deleterious suspect deleterious germline somatic homologous recombination repair hrr gene mutation progress follow prior treatment new hormonal agent base positive result phase profound trial pdufa date set second quarter indication review eu june merck astrazeneca present result phase solo trial evaluate lynparza compare chemotherapy treatment platinumsensitive relapse patient gbrcam advanced ovarian cancer receive prior line chemotherapy result trial show statisticallysignificant clinicallymeaningful improvement objective response rate orr lynparza arm compare chemotherapy arm key secondary endpoint pfs significantly increase lynparza arm compare chemotherapy arm result present asco annual meeting mk selumetinib mek inhibitor codevelope strategic collaboration astrazeneca selumetinib priority review fda potential new medicine pediatric patient age year old neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas regulatory submission base positive result national cancer institute cancer therapy evaluation programsponsore sprint phase stratum trial pdufa date set second quarter v review japan initial indication female prevention certain hpvrelate disease precursor february fda accept priority review supplemental bla gardasil prevention certain head neck cancer cause vaccinetype hpv female male year age fda set pdufa date june addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss lynparza addition indication review discuss phase development combination keytruda treatment nsclc lenvima orally available tyrosine kinase inhibitor currently approve certain type thyroid cancer hcc combination certain patient rcc codevelope strategic collaboration eisai pursuant agreement company jointly initiate clinical study evaluate keytrudalenvima combination type cancer endometrial cancer nsclc hcc hnscc bladder cancer melanoma basket trial target multiple cancer type fda grant breakthrough therapy designation table content keytruda combination lenvima potential treatment patient advance andor metastatic rcc potential treatment patient unresectable hcc amenable locoregional treatment mk gefapixant selective nonnarcotic orallyadministere pxreceptor antagonist investigate phase trial treatment refractory chronic cough phase trial treatment woman endometriosisrelate pain mk vericiguat sgc stimulator potential treatment patient worsen chronic heart failure develop worldwide strategic collaboration merck bayer vericiguat study patient suffer chronic heart failure reduce ejection fraction phase clinical trial chronic heart failure preserve ejection fraction phase clinical trial november merck announce phase victoria study evaluate efficacy safety vericiguat meet primary efficacy endpoint vericiguat reduce risk composite endpoint heart failure hospitalization cardiovascular death patient worsen chronic heart failure reduce ejection fraction compare placebo give combination available heart failure therapie result victoria study present upcoming medical meeting v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiate phase study adult population prevention invasive pneumococcal disease currently phase adult study ongoing include study healthy adult year age old adult risk factor pneumococcal disease infect hiv recipient allogeneic hematopoietic stem cell transplant october merck begin phase study pediatric population currently study ongoing include study healthy infant child afflict sickle cell disease v receive breakthrough therapy designation fda prevention invasive pneumococcal disease cause vaccine serotype pediatric patient week year age adult chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect cancer additional claim line extension formulation inline product show table content phase phase phase entry date review cancer cancer new molecular entitiesvaccine mk keytruda mk keytruda pediatric neurofibromatosis type advanced solid tumor biliary tract september mk selumetinib mk breast october hpv vaccine renal cell carcinoma cervical october eu v human papillomavirus valent vaccine mk colorectal november recombinant jpn solid tumor cutaneous squamous cell carcinoma certain supplemental filing mk lynparza august eu cancer advance solid tumor endometrial august eu mk keytruda mk vicriviroc esophageal december eu firstline metastatic nonsmallcell lung colorectal gastric eu cancer keynote eu mk lenvima hepatocellular eu firstline metastatic gastric cancer biliary tract mesothelioma keynote jpn v nasopharyngeal april recurrent locally advanced metastatic melanoma ovarian december esophageal cancer keynote mk prostate jpn nonsmallcell lung smallcell lung eu recurrent andor metastatic cutaneous mk mk lynparza squamous cell carcinoma hematological malignancies nonsmallcell lung june keynote mk mk lenvima alternative dose regiman hematological malignancy bladder qw nonsmallcell lung endometrial june eu mk lynparza mk head neck squamous cell carcinoma firstline gbrcam pancreatic cancer nonsmallcell lung february polo eu mk melanoma march firstline maintenance newly diagnose nonsmallcell lung nonsmallcell lung march advance ovarian cancer paola cytomegalovirus cough eu v mk gefapixant march metastatic prostate cancer profound hiv infection heart failure eu mk islatravir mk vericiguat september footnote overgrowth syndrome hiv infection develop collaboration mk mka islatravirdoravirine february develop combination pediatric neurofibromatosis type pneumoconjugate vaccine keytruda mk selumetinib eu v june company receive crl february respiratory syncytial virus merck review letter mk discuss step fda schizophrenia mk employees december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group restructuring activity early merck approve new global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructure program include action associate plan spinoff newco company continue evaluate global footprint overall operating model subsequently identify additional action restructure program identify action time action currently contemplate restructure program expect substantially complete end action previous global restructuring program substantially complete environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome table content matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial condition result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states percentage total company sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec address website wwwsecgov addition company provide charge copy annual report include financial statement schedule write request shareholder office secretary merck co inc galloping hill road k kenilworth nj usa companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print shareholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company dependent patent right patent right invalidate circumvent business materially adversely affect patent protection consider aggregate material importance company market human health animal health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing table content sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company defend patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate nda fda seek market generic form company product prior expiration relevant patent own license company company normally respond defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation certain foreign market relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company launch commercially successful product replace lose sale addition product measure fair value capitalize connection acquisition experience difficulty market negatively affect product cash flow company recognize material noncash impairment charge respect value product chart list patent protection certain company market product patent protection candidate phase clinical development set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial condition prospect example patent provide eu market exclusivity certain form noxafil expire july december respectively company anticipate significant decline eu noxafil sales patent provide market exclusivity nuvare expire april generic competition begin december company anticipate rapid substantial decline nuvare sale result generic competition addition patent provide market exclusivity januvia janumet expire july sixmonth pediatric exclusivity extend date patent provide market exclusivity januvia eu expire july pediatric exclusivity extend date september finally spc provide market exclusivity janumet eu expire april company anticipate sale januvia janumet market decline substantially patent expiry table content key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company ability generate profit operate cash flow depend largely continue profitability company key product keytruda gardasilgardasil januvia janumet bridion particular company oncology portfolio lead keytruda represent majority company revenue earning growth result company dependence key product event adversely affect product market product significant adverse impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop collaboration joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial condition prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow table content finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication anticipate labeling uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition certain collaboration failure successfully develop market new product short term long term material adverse effect company business result operations cash flow financial condition prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include eu japan china united states fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case reduction cost drug fda foreign regulatory authority include japan china substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent selling product jurisdiction company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval decrease demand company product include follow result postapproval phase trial study rereview product market recall loss marketing approval product market change government standard public expectation safety efficacy quality labeling change scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse table content label market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pmda chinas nmpa increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity addition dissemination promotional material evolve digital channel serve increase visibility scrutiny marketplace company face intense competition low cost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states eu united states eu political pressure reduce spending prescription drug lead legislation measure encourage use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial condition prospect company face intense competition competitor product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use well insurance coverage reimbursement level effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial condition prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product company face continue pricing pressure respect product company face continue pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca iii state activity aim increase price transparency include new law note item competition health care environment health table content care environment government regulation change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition united states large customer receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company annually post website pricing transparency report united states report provide company average annual list price net price increase company portfolio date company gross sale reduce approximately result rebate discount return outside united states numerous major market include eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine occur furthermore government order reprice specific product determine use product exceed certain threshold define applicable repricing rule example pursuant repricing rule japanese government reduce price keytruda effective february additionally keytruda subject significant price reduction april provision japanese pricing rule company expect pricing pressure continue future health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider executive branch congress state legislature united states enact major health care reform legislation form aca insurance market reform advance state federal insurance exchange launch aca increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal b drug discount program aca require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap ie socalle donut hole increase extended biosimilar product company revenue reduce approximately million requirement pharmaceutical manufacturer require pay annual nontax deductible health care reform fee company record million cost annual fee center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs impact change result issuance rule material merck time company await guidance cms aspect rule defer later implementation include definition constitute product line extension delay participation territory medicaid drug rebate program april company evaluate financial impact element effective addition discuss competition health care environment administration recently propose draft rule allow importation certain lowercost prescription drug canada rule finalize propose state certain nonfederal governmental entity able submit importation program proposal fda review authorization twoyear program opportunity extend year public comment period propose rule expire march follow comment period fda review finalize proposal state table content party submit plan comply federal rule propose rule adopt likely time state party actually implement importation plan october administration issue advance notice propose rulemaking implement international pricing index ipi model united states product cover medicare b proposal reduce medicare b payment drug base market basket international price allow private sector vendor negotiate price drug title drug compete physician hospital business change physician reimbursement medicare b current model eliminate buy bill system instead pay physician base flat fee approximate revenue currently receive drug public comment ipi proposal accept late unclear agency issue propose rule ipi model adoption propose rule material adverse effect company business result operation financial condition company predict likelihood additional future change health care industry general pharmaceutical industry particular impact company business cash flow result operation financial condition prospect company increasingly dependent sophisticated software application compute infrastructure company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation company target future cyberattack company increasingly dependent sophisticated software application complex information technology system compute infrastructure collectively system conduct critical operation certain system manage host provide party assist conduct company business disruption degradation manipulation system intentional accidental mean company employee party authorize access unauthorized party adversely affect key business process cyberattack company system thirdparty provider system cloudbase system result exposure confidential information modification critical datum andor failure critical operation misuse system result disclosure sensitive personal information theft trade secret intellectual property confidential business information company continue leverage new innovative technology enterprise improve efficacy efficiency business process use create new risk company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation result loss company insurance coverage insure loss result cyberattack receive proceed connection cyber attack dispute certain insurer availability insurance coverage claim relate cyberattack company implement variety measure enhance modernize system guard similar attack future pursue enterprisewide effort enhance company resiliency future cyberattack include incident similar attack objective effort protect future cyberattack improve speed company recovery attack enable continued business operation great extent possible recovery period aggregate impact cyberattack network disruption include cyberattack company operation financial condition material date company continue target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system effort thirdparty provider protect system successful prevent disruption companys operation include manufacture research sale operation disruption past future result loss revenue loss critical sensitive information company company thirdparty provider database system past future result financial legal business reputational harm company substantial remediation cost table content company subject variety international law regulation company currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business cash flow result operation financial condition prospect company law regulation include additional healthcare reform initiatives united states country include additional mandatory discount fee ii foreign corrupt practice act antibribery corruption law iii new law regulation judicial governmental decision affect pricing drug reimbursement access marketing jurisdiction iv change intellectual property law v change accounting standard vi new increase datum privacy regulation enforcement particularly eu united states vii legislative mandate preference local manufacturing pharmaceutical vaccine product viii emerge new global regulatory requirement report payment value transfer healthcare professional ix environmental regulation x potential impact importation restriction embargo trade sanction legislative andor regulatory change uncertainty global economic condition costreduction measure take certain government negatively affect company operating result uncertainty global economic geopolitical condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial condition prospect global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government thirdpartie low health care cost company anticipate action additional action future continue negatively affect revenue performance credit economic condition worsen result economic currency impact affect market globally material adverse effect company result company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement include imposition trade sanction similar restriction united states government foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease table content united kingdom uk hold referendum voter approve exit eu commonly refer brexit result referendum subsequent negotiation uk leave eu january transitional period apply january december period eu treat uk eu member state uk continue participate eu customs union allow freedom movement people good transitional period eu uk continue negotiate trade agreement formalize term uks future relationship eu company take action certain contingency plan scenario uk eu reach mutually satisfactory understanding future trade agreement possible time predict understanding end understanding reach term vary way result great restriction import export uk eu country increase regulatory complexity andor cross border labor issue materially adversely impact company business operation uk failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel cost materially increase past company experience difficulty delay manufacture certain product include vaccine merck past experienced difficulty manufacture certain product include vaccine addition network cyberattack experienced company june lead disruption company operation include manufacturing operation company future experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture ii delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply addition company experience difficulty delay manufacturing product cause natural disaster hurricane example company lone manufacture plant puerto rico negatively affect hurricane maria manufacturing difficulty result product shortage lead lose sale reputational harm company company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect company business china grow rapidly past year importance china company overall pharmaceutical vaccine business outside united states increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control note health care environment government regulation pricing pressure china increase chinese government take step reduce cost include implement healthcare reform lead acceleration generic table content substitution available pricing pressure exist china health care reform increase pressure acceleration generic substitution government vbp program government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction expansion vbp program remains see addition company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue december new coronavirus know covid prove highly contagious emerge wuhan china outbreak virus cause material disruption chinese economy include health care system negative effect company quarter result time expect material future course duration covid outbreak unknown company currently unable determine outbreak negative effect company result outbreak covid currently limited effect company supply chain drug raw material china outbreak negatively affect certain company clinical trial reason sale emerge market carry significant risk failure maintain company presence emerge market material adverse effect company business cash flow result operation financial condition prospect company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter business development transaction borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate inflation negatively affect company business cash flow result operation financial condition prospect order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful certain company interest rate derivative investment base london interbank offer rate libor portion merck indebtedness bear interest variable interest rate primarily base libor libor subject recent national international regulatory guidance proposal reform cause libor cease exist entirely company expect reasonable alternative libor implement prior target date company predict consequence timing development include increase interest expense require amendment contract reference libor company subject evolve complex tax law result additional liability affect result operation financial condition company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company negatively affect change tax law new tax law affect example tax rate andor revise tax law interpretation domestic foreign jurisdiction table content pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance thirdparty relationship outsource arrangement materially adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company thirdparty service provider key aspect business include development manufacture commercialization product support system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business negative event animal health industry material adverse effect future result operation financial condition future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal african swine fever lead widespread death precautionary destruction reduce consumption demand animal adversely affect company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition successful development testing manufacturing commercialization biologic vaccine particularly human animal health vaccine long complex expensive uncertain process unique risk uncertaintie relate biologic vaccine include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states eu result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic vaccine subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval generally require release manufacture commercial lot manufacture biologic vaccine especially large quantity complex require use innovative technology handle living microorganism lot approve biologic vaccine undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change table content manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic vaccine frequently costly manufacture production ingredient derive live animal plant material biologic vaccine synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead variability manufacturing process lead allegation harm include infection allergic reaction allegation review standard investigation process lead closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost insurance increase significantly company subject substantial number product liability claim item financial statement supplementary datum note contingency environmental liability information company current product liability litigation respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise social medium platform present risk challenge inappropriate andor unauthorized use certain social medium channel cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company product social networking platform damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium policy guide employee appropriate personal professional use social medium company process place completely secure protect information identify new point entry social medium continue expand present new challenge risk relate propose spinoff newco propose spinoff newco complete term timeline currently contemplate achieve expect result february company announce intention spinoff product womens health trust legacy brand biosimilar business new yettobename independent publicly trade company newco distribution newco publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose transaction expect complete half completion spinoff subject number factor condition assurance company able complete spinoff term timeline announce unanticipated development delay prevent adversely affect propose spinoff include limited disruption general financial market condition potential problem delay obtain regulatory tax approval clearance addition consummation propose spinoff require final approval company board director table content cost complete propose spinoff significant addition company unable achieve strategic financial benefit expect achieve spinoff newco company incur significant expense connection spinoff addition company able achieve strategic financial benefit expect result spinoff anticipate benefit spinoff base number assumption prove incorrect follow spinoff price share companys common stock fluctuate significantly company predict effect spinoff trading price share common stock market value share common stock equal great market value share common stock prior spinoff addition price merck common stock volatile time spinoff significant income tax liability spinoff certain relate transaction determine taxable federal income tax purpose company expect prior completion spinoff receive opinion tax counsel conclude thing spinoff outstanding newco share merck shareholder certain relate transaction qualify taxfree merck shareholder section internal revenue code extent cash receive lieu fractional share newco common stock opinion bind internal revenue service irs accordingly company believe risk low irs reach conclusion respect spinoff different conclusion reach opinion opinion rely certain fact assumption representation undertaking merck newco past future conduct company respective business matter incomplete incorrect satisfied alter conclusion party giving opinion propose spinoff ultimately determine taxable company believe unlikely spinoff treat taxable dividend merck shareholder federal income tax purpose merck shareholder incur significant federal income tax liability addition merck recognize taxable gain extent fair market value newco common stock exceed merck tax basis stock date spinoff cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance table content difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product cyberattack company thirdparty provider information technology system disrupt company operation lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states eu legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate propose spinoff delay cost complete spinoff significant expect list consider exhaustive statement potential risk uncertainty risk factor item b unresolved staff comment item property companys corporate headquarter locate kenilworth new jersey company maintain operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal research facility locate rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts south san francisco california elkhorn nebraska animal health principal research facility outside united states locate united kingdom switzerland table content china mercks manufacturing operation headquarter whitehouse station new jersey company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia capital expenditure billion billion billion united states amount billion billion billion abroad expenditure amount billion billion million company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain company believe plant manufacture product suitable intend purpose capacity project capacity include previouslydisclose capital expansion project adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer person age office business experience kenneth c frazier chairman president chief executive officer december sanat chattopadhyay executive vice president president merck manufacturing division march senior vice president operation merck manufacturing division november march frank clyburn executive vice president chief commercial officer january president global oncology business unit october december robert davis executive vice president global services chief financial officer april executive vice president chief financial officer april april richard r deluca jr executive vice president president merck animal health september michael w fleme senior vice president chief ethic compliance officer march senior vice president international legal compliance january march vice president international legal compliance july january julie l gerberde executive vice president chief patient officer strategic communication global public policy population health july executive vice president strategic communication global public policy population health january july rita karachun senior vice president finance global controller march steven c mizell executive vice president chief human resource officer october executive vice president chief human resource officer december october executive vice president human resource monsanto company august december michael nally executive vice president chief marketing officer january president global vaccines global human health september january managing director united kingdom ireland global human health january september roger perlmutter md phd executive vice president president merck research laboratory april executive vice president general counsel corporate secretary january executive vice president general counsel april january partner covington burling llp jennifer zachary january march table content ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk january approximately shareholder record company common stock issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total share purchase period plan approve board director october purchase billion merck share treasury table content performance graph follow graph assume investment december reinvestment dividend companys common share sp index composite peer group major europeanbase pharmaceutical company abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculate market cap weight basis performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation c provide regulation sk liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck co inc subsidiarie million share amount result year sale cost sale sell general administrative research development restructuring cost income expense net income taxis tax income net income net loss income attributable noncontrolle interest net income attributable merck co inc basic earning common share attributable merck co inc common shareholder earning common share assume dilution attributable merck co inc common shareholder cash dividend declare cash dividend declare common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include charge acquisition peloton therapeutics inc amount include charge relate formation collaboration eisai co ltd amount include provisional net tax charge relate enactment tax legislation charge relate formation collaboration astrazeneca plc amount include charge relate settlement worldwide patent litigation relate keytruda amount include net charge relate settlement vioxx shareholder class action litigation foreign exchange loss relate venezuela gain disposition business asset favorable benefit certain tax item table content item management discussion analysis financial condition result operation follow section generally discuss result yeartoyear comparison discussion result yeartoyear comparison include find management discussion analysis financial condition result operation ii item company annual report fiscal year end december file february description mercks business merck co inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company recently sell certain business healthcare service segment process divest remain business company continue look investment opportunity area health care approach investment shift venture capital investment party oppose whollyowne business alliance segment primarily include activity company relationship astrazeneca lp relate sale nexium prilosec conclude plan spinoff womens health legacy brand biosimilar new company february merck announce intention spinoff product womens health trust legacy brand biosimilar business new yettobename independent publicly trade company newco distribution newco publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose legacy brand include transaction consist dermatology pain respiratory select cardiovascular product include zetia vytorin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan newco development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete half subject market certain condition overview merck performance demonstrate execution commercial research operation drive focus key growth driver innovative pipeline investment reinforce company sciencele strategy merck enhance portfolio pipeline external innovation increase investment new capital project focus primarily expand manufacturing capacity merck key business return capital shareholder table content worldwide sale billion increase compare include unfavorable effect foreign exchange sale increase drive primarily merck growth pillar oncology human health vaccine certain hospital acute care product animal health growth area partially offset ongoing effect generic competition particularly diversify brand cardiovascular franchise competitive pressure particularly diabete virology franchise merck continue prioritize business development aim enhance portfolio strengthen pipeline execute business development transaction expand oncology presence merck complete acquisition peloton therapeutics inc peloton clinicalstage biopharmaceutical company focus development novel small molecule therapeutic candidate treatment cancer disease immune design latestage immunotherapy company employ nextgeneration vivo approach enable bodys immune system fight disease merck announce agreement acquire arqule inc arqule biopharmaceutical company focus kinase inhibitor discovery development treatment cancer disease acquisition close january augment mercks animal health business company acquire antelliq group antelliq leader digital animal identification traceability monitoring solution company receive numerous regulatory approval progress important pipeline candidate clinical development oncology keytruda receive multiple additional approval united states european union eu china japan monotherapy therapeutic area nonsmallcell lung cancer nsclc smallcell lung cancer sclc esophageal cancer combination axitinib treatment renal cell carcinoma rcc combination chemotherapy head neck squamous cell carcinoma hnscc combination lenvima endometrial carcinoma lynparza develop collaboration astrazeneca plc astrazeneca receive food drug administration fda approval treatment appropriate patient germline brcamutate gbrcam pancreatic cancer european commission ec approval use certain patient advance ovarian cancer advance metastatic breast cancer addition oncology company receive regulatory approval hospital acute care vaccine therapeutic area fda approve recarbrio imipenem cilastatin relebactam injection new combination antibacterial treatment certain patient complicate urinary tract infection cause certain gramnegative microorganism recarbrio approve ec february fda ec approve expand indication zerbaxa treatment patient hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia habpvabp cause certain susceptible gramnegative microorganism additionally ervebo ebola zaire vaccine live vaccine prevention disease cause zaire ebolavirus adult approve united states receive conditional approval eu addition recent regulatory approval discuss company advanced latestage pipeline particularly oncology regulatory submission keytruda lynparza lenvima united states internationally company phase oncology program include keytruda therapeutic area biliary tract breast cervical colorectal cutaneous squamous cell endometrial esophageal gastric hepatocellular mesothelioma nasopharyngeal ovarian prostate smallcell lung cancer lynparza combination keytruda nonsmall cell lung cancer lenvima combination keytruda bladder endometrial head neck melanoma nonsmallcell lung cancer additionally company candidate phase clinical development therapeutic area include v investigational polyvalent conjugate vaccine prevention pneumococcal disease receive breakthrough therapy designation fda prevention invasive pneumococcal disease cause vaccine serotype pediatric patient week year age adult mk gefapixant selective nonnarcotic orallyadministere pxreceptor antagonist develop treatment refractory chronic cough mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti combination doravirine treatment hiv infection mk vericiguat investigational treatment heart failure develop collaboration research development company allocate resource effectively support commercial opportunity near term make necessary investment support longterm growth research development expense reflect high clinical development spending increase investment discovery research early drug development table content november mercks board director approve increase company quarterly dividend raising share share company outstanding common stock company return billion shareholder dividend share repurchase earning common share assume dilution attributable common shareholder ep compare eps year reflect impact acquisition divestiturerelate cost restructuring cost certain item certain item include charge relate acquisition peloton include charge relate formation collaboration eisai co ltd eisai nongaap eps exclude item nongaap income nongaap eps price global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government thirdpartie low health care cost company anticipate action additional action future continue negatively affect revenue performance operating result sale change change exclude exclude million change exchange change exchange united states international total plus international equal total round worldwide sale grew drive primarily high sale oncology franchise reflect strong growth keytruda increase alliance revenue relate lynparza lenvima contribute revenue growth high sale vaccine include gardasilgardasil varivax proquad mmr ii increase sale certain hospital acute care product include bridion high sale animal health product drive revenue growth sale growth partially offset effect generic competition cardiovascular product zetia vytorin hospital acute care product invanz cubicin noxafil oncology product emend product diversified brand franchise biosimilar competition immunology product remicade diversified brand franchise include certain product approach expiration marketing exclusivity long protect patent develop market low sale diabete product januvia janumet hiv product isentressisentress hd partially offset revenue growth sale united states grew drive primarily high sale keytruda combine sale proquad mmr ii varivax bridion high alliance revenue lenvima lynparza revenue growth partially offset low sale januvia janumet invanz emend isentressisentress hd cubicin noxafil international sale grow performance international market lead china total sale billion represent growth compare include unfavorable effect foreign exchange increase international sale primarily reflect growth keytruda gardasilgardasil combine sale proquad mmr ii varivax high alliance revenue lynparza lenvima sale growth partially offset low sale zetia vytorin zepati remicade product diversified brand franchise international sale represent total sale note consolidated financial statement detail sale company product discussion performance select product franchise follow table content pharmaceutical segment oncology change change exclude exclude million change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima na na emend calculation meaningful alliance revenue represent merck share profit product sale net cost sale commercialization cost note consolidated financial statement keytruda antipd therapy approve treatment multiple malignancy include cervical cancer classical hodgkin lymphoma chl esophageal cancer gastric gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc nsclc sclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer primary mediastinal large bcell lymphoma pmbcl rcc urothelial carcinoma keytruda clinical development program include study broad range cancer type research development january fda approve keytruda monotherapy treatment certain patient bacillus calmetteguerin bcgunresponsive highrisk nonmuscle invasive bladder cancer nmibc base result keynote trial july fda approve keytruda monotherapy treatment certain patient recurrent locally advanced metastatic squamous cell carcinoma esophagus tumor express pdl combine positive score cp determine fdaapprove test base result keynote keynote trial june fda approve keytruda monotherapy combination chemotherapy firstline treatment patient metastatic unresectable recurrent hnscc base result pivotal phase keynote trial keytruda initially approve hnscc fda accelerate approval process base datum phase b keynote trial accordance accelerate approval process continue approval contingent verification description clinical benefit demonstrate keynote result fda converting accelerate approval regular approval keytruda approve indication ec november japans ministry health labour welfare mhlw december june fda approve keytruda monotherapy treatment certain patient metastatic sclc base pooled datum keynote cohort g keynote cohort c clinical trial april fda approve keytruda combination inlyta axitinib tyrosine kinase inhibitor firstline treatment patient advance rcc common type kidney cancer base finding pivotal phase keynote trial keytruda approve indication ec september japans mhlw december april fda approve expand label keytruda monotherapy firstline treatment patient nsclc express pd l tumor proportion score tps determine fdaapproved test egfr alk genomic tumor aberration stage iii disease patient candidate surgical resection definitive chemoradiation metastatic disease approval base result phase keynote trial september fda approve combination keytruda plus lenvima treatment certain patient advance endometrial carcinoma msih mismatch repair deficient table content march ec approve keytruda combination carboplatin paclitaxel nabpaclitaxel firstline treatment adult metastatic squamous nsclc base datum phase keynote trial keytruda approve indication fda october april ec approve new extended dose schedule mg week qw deliver intravenous infusion minute approve monotherapy indication eu qw dose available addition approve dose keytruda mg week qw infuse minute additionally keytruda receive follow approval china national medical products administration nmpa combination pemetrexed platinum chemotherapy firstline treatment patient metastatic nonsquamous nsclc egfr alk genomic tumor aberration base datum pivotal phase keynote trial monotherapy firstline treatment patient locally advanced metastatic nsclc tumor express pdl determine nmpaapprove test egfr alk genomic tumor aberration base result phase keynote trial combination carboplatin paclitaxel firstline treatment patient metastatic squamous nsclc base finding pivotal phase keynote trial global sale keytruda grew drive high demand company continue launch keytruda multiple new indication globally sale united states continue build multiple approve indication particular treatment nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc uptake recently launch rcc adjuvant melanoma indication indication contribute sale growth include hnscc urothelial carcinoma melanoma msih cancer keytruda sale growth international market drive primarily performance europe japan china reflect increase use treatment nsclc recently approve indication describe company party certain thirdparty license agreement pursuant company pay royalty sale keytruda term significant agreement merck pay royalty worldwide sale keytruda party royalty decline terminate company pay additional royalty worldwide sale keytruda party termination date vary country royalty expire united states major european market royalty include cost sale pursuant repricing rule japanese government reduce price keytruda effective february additionally keytruda subject significant price reduction april provision japanese pricing rule lynparza oral poly adpribose polymerase parp inhibitor develop collaboration astrazeneca enter july note consolidated financial statement approve treatment certain type advance ovarian breast pancreatic cancer increase alliance revenue relate lynparza drive primarily expand use united states eu japan china reflect ongoing launch new indication lynparza receive approval treatment certain type advance ovarian cancer united states december eu japan june china december base result phase solo trial april ec approve lynparza treatment certain adult patient advance breast cancer base result phase olympiad trial additionally december fda approve lynparza maintenance treatment certain adult patient advance pancreatic cancer base result phase polo trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai enter march note consolidated financial statement approve treatment certain type thyroid cancer hcc combination evorolimus certain patient rcc additionally september fda approve combination keytruda plus lenvima treatment certain patient advance endometrial carcinoma msih mismatch repair deficient mark approval combination keytruda plus lenvima increase alliance revenue relate lenvima reflect strong performance treatment hcc follow recent worldwide launch year collaboration activity table content global sale emend prevention chemotherapyinduce postoperative nausea vomiting decline drive primarily low demand pricing united states competition include recent generic competition emend injection follow patent expiry september patent provide market exclusivity emend expire patent provide market exclusivity major european market expire additionally emend injection lose market exclusivity major european market august company anticipate sale emend injection market decline significantly vaccine change change exclude exclude million change exchange change exchange gardasilgardasil proquad mmr ii varivax rotateq worldwide sale gardasilgardasil vaccine help prevent certain cancer disease cause certain type hpv grew drive primarily high demand asia pacific region particularly china high demand certain european market reflect increase vaccination rate boy girl growth partially offset low sale united state sale decline drive borrowing gardasil dose center disease control prevention cdc pediatric vaccine stockpile offset high demand pricing company borrow dose gardasil cdc pediatric vaccine stockpile borrowing reduce sale approximately million company recognize corresponding liability company replenish dose borrow cdc pediatric vaccine stockpile result recognition sale million reversal liability relate borrowing decision japans mhlw suspend active recommendation hpv vaccination review company party certain thirdparty license agreement pursuant company pay royalty sale gardasilgardasil term significant agreement merck pay royalty worldwide sale gardasilgardasil party agreement expire december additional royalty sale gardasilgardasil united states party agreement expire december royalty include cost sale global sale proquad pediatric combination vaccine help protect measle mump rubella varicella grew drive primarily high volume pricing united states volume growth eu largely reflect competitor supply issue worldwide sale mmr ii vaccine help protect measle mump rubella grew drive primarily high sale united sate reflect increase demand measle outbreak high pricing company anticipate sale mmr ii decline drive low expect demand relate few measle outbreak global sale varivax vaccine help prevent chickenpox varicella grew drive primarily government tender latin america high pricing volume growth united states varivax sale expect decline time government tender competition select latin american market global sale rotateq vaccine help protect rotavirus gastroenteritis infant child grew drive primarily continue uptake launch china high volume united states partially offset low volume latin america table content december fda approve ervebo prevention disease cause zaire ebolavirus individual year age old previously announce merck working initiate manufacturing license dose expect dose start available approximately quarter merck work closely government world health organization unicef gavi vaccine alliance plan eventual license dose support future public health preparedness response effort zaire ebolavirus disease merck seek profit sale vaccine ensure vaccine sustainable recover manufacture operational cost associate program ervebo grant conditional marking authorization ec additionally merck submission african country national regulatory authority collaboration african vaccine regulatory forum allow vaccine register african country consider atrisk ebola outbreak february merck confirm african country approve ervebo approval additional country africa anticipate near future hospital acute care change change exclude exclude million change exchange change exchange bridion noxafil invanz cubicin global sale bridion reversal type neuromuscular block agent surgery grew drive high demand globally particularly united states worldwide sales noxafil prevention invasive fungal infection decline drive primarily generic competition united states patent provide market exclusivity certain form noxafil represent majority noxafil sale expire july accordingly company experience decline noxafil sale result generic competition expect decline continue additionally patent noxafil expire number major european market december result company anticipate sale noxafil market decline significantly future period global sale invanz treatment certain infection decline driven generic competition united states patent provide market exclusivity invanz expire november generic competition begin second half company subsequently experience significant decline invanz sales united states result generic competition lose invanz sale global sale cubicin iv antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism decline result primarily ongoing generic competition united states follow expiration composition patent cubicin fda ec approve expand indication zerbaxa treatment habpvabp cause certain susceptible gramnegative microorganism base result pivotal phase aspectnp trial zerbaxa previously approve united states eu treatment adult certain complicated urinary tract intraabdominal infection july fda approve recarbrio injection new combination antibacterial treatment adult limit alternative treatment option complicate urinary tract infection complicate intraabdominal infection cause certain susceptible gramnegative microorganism recarbrio approve ec february merck anticipate make recarbrio available half january fda approve dificid fidaxomicin oral suspension dificid tablet treatment clostridioide clostridium difficileassociate diarrhea child age month old table content immunology change change exclude exclude million change exchange change exchange simponi remicade sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey decline drive unfavorable effect foreign exchange low pricing europe sale simponi unfavorably affected launch biosimilar compete product company expect competition continue unfavorably affect sale simponi sale remicade treatment inflammatory disease market company europe russia turkey decline drive ongoing biosimilar competition company marketing territory company lose market exclusivity remicade major european market long market exclusivity marketing territory company experience pricing volume decline market result biosimilar competition expect decline continue virology change change exclude exclude million change exchange change exchange isentressisentress hd worldwide sale isentressisentress hd hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection decline primarily reflect low demand united states eu competitive pressure september fda approve supplemental new drug application nda pifeltro doravirine combination antiretroviral agent delstrigo doravirinelamivudinetenofovir disoproxil fumarate complete regimen expand indication include adult patient hiv infection virologically suppress stable antiretroviral regimen cardiovascular change change exclude exclude million change exchange change exchange zetiavytorin atozet rosuzet adempas combine global sale zetia market country outside united states ezetrol vytorin market outside united states inegy medicine lower ldl cholesterol decline drive primarily low sale eu eu patent ezetrol inegy expire april april respectively accordingly company experience sale decline market result generic competition expect decline continue sale decline attributable loss exclusivity australia merck lose market exclusivity united states zetia vytorin subsequently lose nearly sale product result generic competition sale atozet market outside united states medicine lower ldl cholesterol grew primarily drive high demand eu korea sale rosuzet market outside united states medicine lower ldl cholesterol double primarily drive launch japan high demand korea table content adempas cardiovascular drug treatment pulmonary arterial hypertension worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulator include adempas note consolidated financial statement increase alliance revenue drive high profit bayer high sale adempas merck marketing territory diabetes change change exclude exclude million change exchange change exchange januviajanumet worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete decline result continued pricing pressure united states partially offset high demand international market company expect pricing pressure continue patent provide market exclusivity januvia janumet united states expire july sixmonth pediatric exclusivity extend date patent provide market exclusivity januvia eu expire july pediatric exclusivity extend date september supplementary patent certificate provide market exclusivity janumet eu expire april company anticipate sale januvia janumet market decline substantially patent expiry women health change change exclude exclude million change exchange change exchange nuvare implanonnexplanon worldwide sale nuvare vaginal contraceptive product decline drive primarily low demand eu generic competition largely offset high sale united states reflect high pricing partially offset low demand patent provide market exclusivity nuvare expire april generic competition begin december company anticipate rapid substantial decline nuvare sale result generic competition worldwide sale implanonnexplanon singlerod subdermal contraceptive implant grew primarily drive high demand pricing united states biosimilar change change exclude exclude million change exchange change exchange biosimilar calculation meaningful biosimilar product market company pursuant agreement samsung bioepis co ltd samsung develop commercialize multiple prespecified biosimilar candidate currently company market renflexis infliximababda tumor necrosis factor tnf antagonist biosimilar remicade infliximab treatment certain inflammatory disease ontruzant trastuzumabdttb human epidermal growth factor receptor neu receptor antagonist biosimilar herceptin trastuzumab treatment herpositive breast cancer overexpresse gastric cancer brenzys etanercept biosimilar tnf antagonist biosimilar enbrel treatment certain inflammatory disease merck commercialization territory agreement vary product sale growth biosimilar drive continued uptake renflexis united states launch continue uptake ontruzant eu launch launch brenzys brazil table content animal health segment change change exclude exclude million change exchange change exchange livestock companion animal sale livestock product grow predominantly product obtain april acquisition antelliq leader digital animal identification traceability monitoring solution note consolidated financial statement growth sale livestock product drive high demand aqua swine product sale companion animal product grew drive primarily high demand bravecto line product parasitic control cost expense million change change cost sale sell general administrative research development restructuring cost income expense net great cost sale cost sale billion compare billion cost sale include amortization intangible asset record connection business acquisition total billion compare billion cost sale include amortization amount capitalize connection collaboration million compare million note consolidated financial statement additionally cost include intangible asset impairment charge million relate market product record connection business acquisition note consolidated financial statement company recognize additional noncash impairment charge future relate intangible asset measure fair value capitalize connection business acquisition charge material cost include million charge relate termination collaboration agreement samsung insulin glargine note consolidated financial statement include cost sale expense associate restructuring activity amount million compare million primarily reflect accelerated depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare gross margin improvement reflect charge record connection termination collaboration agreement samsung note favorable product mix low amortization intangible asset note improvement gross margin partially offset unfavorable manufacturing variance inventory writeoff pricing pressure high restructuring cost sell general administrative selling general administrative sga expense billion increase compare drive primarily high administrative cost acquisition divestiturerelate cost largely related acquisition antelliq promotional expense primarily support strategic brand restructuring cost partially offset favorable effect foreign exchange low selling cost sga expense include restructure cost million relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss sga expense include acquisition divestiturerelated cost million compare table content million consist integration transaction certain cost relate business acquisition divestiture research development research development rd expense billion increase compare increase drive primarily million charge acquisition peloton note consolidated financial statement high expense relate clinical development increase investment discovery research early drug development increase rd expense partially offset billion charge relate formation oncology collaboration eisai note consolidated financial statement million charge relate acquisition viralytic limited viralytic note consolidated financial statement favorable effect foreign exchange rd expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity billion compare billion include rd expense animal health research cost license cost cost incur division support rd activity include depreciation production general administrative aggregate billion billion rd expense include inprocess research development iprd impairment charge million million respectively note consolidated financial statement company recognize additional noncash impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business acquisition charge material addition rd expense include expense income relate change estimate fair value measurement liability contingent consideration record connection business acquisition company record net reduction expense million million respectively relate change estimate restructure cost early merck approve new global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructure program include action associate plan spinoff newco company continue evaluate global footprint overall operating model subsequently identify additional action restructure program identify action time action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company expect record charge approximately million related restructuring program company anticipate action restructure program result annual net cost saving approximately million end action previous global restructuring program substantially complete restructure cost primarily represent separation relate cost associate restructuring activity million million separation cost incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate include restructuring cost asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include cost sale sell general administrative research development company record aggregate pretax cost million million related restructuring program activity note consolidated financial statement table content income expense net detail component income expense net note consolidated financial statement segment profit million pharmaceutical segment profit animal health segment profit nonreportable segment profit income taxis pharmaceutical segment profit comprise segment sale standard cost sga expense directly incur segment animal health segment profit comprise segment sale cost sale sga rd expense directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur mrl general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit cost related restructuring activity acquisition divestiturerelated cost include amortization purchase accounting adjustment intangible asset impairment charge change estimate fair value measurement liability contingent consideration additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale result change companys internal reporting structure certain cost previously include pharmaceutical segment include nonsegment expense mrl prior period pharmaceutical segment profit recast reflect change comparable basis pharmaceutical segment profit grew compare drive primarily high sale low selling cost animal health segment profit declined drive primarily unfavorable product mix high investment sell product development unfavorable effect foreign exchange partially offset high sale taxis income effective income tax rate reflect impact acquisition divestiturerelated cost restructure cost beneficial impact foreign earning include product mix effective income tax rate reflect favorable impact million net tax benefit relate settlement certain federal income tax matter note consolidated financial statement reversal tax reserve establish connection divestiture merck consumer care mcc business lapse statute limitation addition effective income tax rate reflect unfavorable impact charge acquisition peloton tax benefit recognize charge million relate finalization treasury regulation transition tax associate enactment tax legislation know tax cut job act tcja note consolidated financial statement effective income tax rate include measurementperiod adjustment provisional amount record associate enactment tcja include million relate transition tax addition effective income tax rate reflect unfavorable impact charge record connection formation collaboration eisai charge relate termination collaboration agreement samsung tax benefit recognize table content net loss income attributable noncontrolle interest net loss income attributable noncontrolle interest million compare million loss drive primarily portion goodwill impairment charge relate certain business healthcare service segment attributable noncontrolle interest net income earning common share net income attributable merck co inc billion billion eps nongaap income nongaap ep nongaap income nongaap eps alternative view company performance merck provide management believe information enhance investor understand company result permit investor understand management assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost certain item exclude item significant component understand assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps management use measure internally plan forecasting purpose measure performance company metric addition senior management annual compensation derive nongaap pretax income nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance generally accept accounting principle united states gaap table content reconciliation gaap financial measure nongaap financial measure follow million share amount income taxis report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost item charge acquisition peloton charge relate formation oncology collaboration eisai charge relate termination collaboration samsung charge acquisition viralytic charge relate formation oncology collaboration astrazeneca nongaap income taxis tax income report gaap estimate tax benefit exclude item net tax charge relate enactment tcja subsequent finalization relate treasury regulation net tax benefit settlement certain federal income tax matter tax benefit reversal tax reserve relate divestiture mcc tax benefit relate settlement state income tax matter nongaap taxes income nongaap net income net loss income attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income attributable noncontrolle interest nongaap net income attributable merck co inc eps assume dilution report gaap ep difference nongaap ep assume dilution estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment provisional note consolidated financial statement acquisition divestiturerelated cost nongaap income nongaap eps exclude impact certain amount record connection business acquisition divestiture amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration exclude integration transaction certain cost associate business acquisition divestiture restructure cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site table content close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost certain item item adjust evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge acquisition peloton note consolidated financial statement tax charge relate finalization treasury regulation relate tcja net tax benefit relate settlement certain federal income tax matter tax benefit relate reversal tax reserve establish connection divestiture mcc note consolidated financial statement exclude nongaap income nongaap eps charge relate formation collaboration eisai note consolidated financial statement charge relate termination collaboration agreement samsung insulin glargine note consolidated financial statement charge acquisition viralytic note consolidated financial statement measurementperiod adjustment relate provisional amount record tcja note consolidated financial statement exclude nongaap income nongaap eps charge relate formation collaboration astrazeneca note consolidated financial statement provisional net tax charge relate enactment tcja net tax benefit relate settlement certain federal income tax matter tax benefit relate settlement state income tax matter note consolidated financial statement research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally keytruda antipd therapy approve treatment cancer clinical development expand indication approval result broad clinical development program currently consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nonsmallcell lung ovarian pmbcl prostate renal smallcell lung triplenegative breast urothelial currently phase clinical development trial plan cancer keytruda review eu monotherapy firstline treatment patient stage iii nsclc candidate surgical resection definitive chemoradiation metastatic nsclc tumor express pdl tps egfr alk genomic tumor aberration base result phase keynote trial keytruda review japan monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma base result pivotal phase keynote trial keytruda review japan monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma base result phase keynote trial merck decision withdraw type ii variation application keytruda indication eu october fda accept supplemental biologic license application bla seeking use keytruda treatment patient recurrent andor metastatic cutaneous squamous cell carcinoma cscc table content curable surgery radiation base result keynote trial fda set prescription drug user fee act pdufa date june february merck announce fda issue complete response letter merck supplemental bla seek update dose frequency keytruda include mg dose infuse minute everysixweek qw option multiple indication submit application base pharmacokinetic modeling simulation datum present american society clinical oncology asco annual meeting datum support ec approval mg qw dose keytruda monotherapy indication march merck review letter discuss step fda additionally keytruda receive breakthrough therapy designation fda combination neoadjuvant chemotherapy treatment highrisk earlystage triplenegative breast cancer tnbc combination enfortumab vedotin firstline set treatment patient unresectable locally advanced metastatic urothelial cancer eligible cisplatincontaine chemotherapy fda breakthrough therapy designation intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint september merck announce result pivotal neoadjuvantadjuvant phase keynote trial patient earlystage tnbc trial investigate regimen neoadjuvant keytruda plus chemotherapy follow adjuvant keytruda monotherapy keytruda regiman compare regimen neoadjuvant chemotherapy follow adjuvant placebo chemotherapyplacebo regimen interim finding present european society medical oncology esmo congress neoadjuvant phase keytruda plus chemotherapy result statistically significant increase pathological complete response pcr versus chemotherapy patient earlystage tnbc improvement see add keytruda neoadjuvant chemotherapy observe regardless pdl expression dual primary endpoint eventfreesurvival ef median followup month keytruda regimen reduce risk progression neoadjuvant phase recurrence adjuvant phase compare chemotherapyplacebo regimen merck continue discuss interim analysis datum keynote regulatory authority keytruda breast cancer clinical development program encompass internal external collaborative study february merck announce pivotal phase keynote trial investigate keytruda combination chemotherapy meet dual primary endpoint progressionfree survival pfs patient metastatic triplenegative breast cancer mtnbc tumor express pdl cp base interim analysis conduct independent datum monitor committee dmc firstline treatment keytruda combination chemotherapy nabpaclitaxel paclitaxel gemcitabinecarboplatin demonstrate statistically significant clinically meaningful improvement pfs compare chemotherapy patient base recommendation dmc trial continue change evaluate dual primary endpoint overall survival os merck announce phase keynote trial evaluate keytruda monotherapy second thirdline treatment patient metastatic tnbc meet prespecified primary endpoint superior os compare chemotherapy endpoint formally test study protocol primary endpoint os meet june merck announce result pivotal phase keynote trial evaluate keytruda monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma monotherapy arm study keytruda meet primary endpoint demonstrate noninferiority chemotherapy current standard care os patient tumor express pdl cp combination arm keynote keytruda plus chemotherapy find statistically superior os cp cps pfs cps compare chemotherapy result present asco annual meeting september fda approve keytruda thirdline treatment previously treat patient recurrent locally advanced metastatic gastric gastroesophageal junction cancer tumor express pdl cp determine fdaapproved test keynote potential confirmatory trial accelerate thirdline approval addition keynote additional firstline phase table content study merck gastric clinical program include keynote keynote keynote neoadjuvant adjuvant treatment set january merck announce phase keynote trial investigate keytruda combination chemotherapy meet dual primary endpoint pfs firstline treatment patient extensive stage sclc final analysis study improvement os patient treat keytruda combination chemotherapy compare chemotherapy os result meet statistical significance prespecified statistical plan result present upcoming medical meeting discuss regulatory authority lynparza oral parp inhibitor currently approve certain type advance ovarian breast pancreatic cancer codevelope multiple cancer type collaboration astrazeneca note consolidated financial statement lynparza review eu firstline maintenance monotherapy patient gbrcam metastatic pancreatic cancer disease progress follow firstline platinumbase chemotherapy lynparza approve indication fda december base result phase polo trial decision european medicine agency ema expect second half january fda accept supplemental nda lynparza combination bevacizumab maintenance treatment woman advance ovarian cancer disease show complete partial response firstline treatment platinumbase chemotherapy bevacizumab base result pivotal phase paola trial pdufa date set second quarter indication review eu january fda accept priority review supplemental nda lynparza treatment patient metastatic castrationresistant prostate cancer mcrpc deleterious suspect deleterious germline somatic homologous recombination repair hrr gene mutation progress follow prior treatment new hormonal agent base positive result phase profound trial pdufa date set second quarter indication review eu june merck astrazeneca present result phase solo trial evaluate lynparza compare chemotherapy treatment platinumsensitive relapse patient gbrcam advanced ovarian cancer receive prior line chemotherapy result trial show statisticallysignificant clinicallymeaningful improvement objective response rate orr lynparza arm compare chemotherapy arm key secondary endpoint pfs significantly increase lynparza arm compare chemotherapy arm result present asco annual meeting mk selumetinib mek inhibitor codevelope strategic collaboration astrazeneca note consolidated financial statement selumetinib priority review fda potential new medicine pediatric patient age year old neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas regulatory submission base positive result national cancer institute cancer therapy evaluation programsponsore sprint phase stratum trial pdufa date set second quarter v review japan initial indication female prevention certain hpvrelate disease precursor february fda accept priority review supplemental bla gardasil prevention certain head neck cancer cause vaccinetype hpv female male year age fda set pdufa date june addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss lynparza addition indication review discuss phase development combination keytruda treatment nsclc lenvima orally available tyrosine kinase inhibitor currently approve certain type thyroid cancer hcc combination certain patient rcc codevelope strategic collaboration eisai note consolidated financial statement pursuant agreement company jointly table content initiate clinical study evaluate keytrudalenvima combination type cancer endometrial cancer nsclc hcc hnscc bladder cancer melanoma basket trial target multiple cancer type fda grant breakthrough therapy designation keytruda combination lenvima potential treatment patient advance andor metastatic rcc potential treatment patient unresectable hcc amenable locoregional treatment mk gefapixant selective nonnarcotic orallyadministere pxreceptor antagonist investigate phase trial treatment refractory chronic cough phase trial treatment woman endometriosisrelate pain mk vericiguat sgc stimulator potential treatment patient worsen chronic heart failure develop worldwide strategic collaboration merck bayer note consolidated financial statement vericiguat studied patient suffer chronic heart failure reduce ejection fraction phase clinical trial chronic heart failure preserve ejection fraction phase clinical trial november merck announce phase victoria study evaluate efficacy safety vericiguat meet primary efficacy endpoint vericiguat reduce risk composite endpoint heart failure hospitalization cardiovascular death patient worsen chronic heart failure reduce ejection fraction compare placebo give combination available heart failure therapie result victoria study present upcoming medical meeting v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiate phase study adult population prevention invasive pneumococcal disease currently phase adult study ongoing include study healthy adult year age old adult risk factor pneumococcal disease infect hiv recipient allogeneic hematopoietic stem cell transplant october merck begin phase study pediatric population currently study ongoing include study healthy infant child afflict sickle cell disease v receive breakthrough therapy designation fda prevention invasive pneumococcal disease cause vaccine serotype pediatric patient week year age adult company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit ensure externally source program remain important component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease diabete metabolic disease infectious disease neuroscience pain respiratory disease vaccine acquire inprocess research development connection business acquisition company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date table content circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record iprd impairment charge research development expense million million million respectively note consolidated financial statement additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent transaction describe merck actively monitor landscape growth opportunity meet company strategic criterion april merck acquire immune design latestage immunotherapy company employ nextgeneration vivo approach enable bodys immune system fight disease million cash transaction account acquisition business merck recognize intangible asset iprd million cash million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assume july merck acquire peloton clinicalstage biopharmaceutical company focus development novel small molecule therapeutic candidate target hypoxiainducible factor hif treatment patient cancer nononcology disease peloton lead candidate mk pt novel oral hif inhibitor latestage development renal cell carcinoma merck upfront payment billion cash additionally peloton shareholder eligible receive million regulatory approval million commercial sale united states billion salesbased milestone transaction account acquisition asset merck record cash million defer tax liability million net liability million acquisition date research development expense million relate transaction january merck acquire arqule inc arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease billion arqule lead investigational candidate mk arq novel oral bruton tyrosine kinase btk inhibitor currently phase dose expansion study treatment bcell malignancy company process determine preliminary fair value asset acquire liability assume total consideration transfer transaction account acquisition business capital expenditure capital expenditure billion billion billion expenditure united states billion billion billion increase capital expenditure reflect investment new capital project focus primarily increase manufacturing capacity merck key product previously announce company plan invest billion new capital project depreciation expense billion billion billion billion billion billion relate location united states total depreciation expense include accelerate depreciation million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder table content select datum million work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion compare billion reflect strong operating performance increase account receivable factoring discuss cash provide operating activity continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder cash investing activity billion compare cash provide investing activity billion change drive primarily low proceed sale security investment acquisition antelliq peloton high capital expenditure partially offset low purchase security investment cash financing activity billion compare billion low use cash financing activity drive primarily proceed issuance debt low purchase treasury stock reflect accelerated share repurchase asr program discuss low payment debt partially offset repayment shortterm borrowing high dividend pay shareholder low proceed exercise stock option company account receivable factoring agreement financial institution certain country sell account receivable note consolidated financial statement company factor billion billion account receivable fourth quarter respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million behalf financial institution remit january net cash flow collection report financing activity consolidate statement cash flow company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation unrecognize tax benefit transition tax relate enactment tcja milestone payment relate collaboration lease include future inventory purchase company commit connection certain divestiture december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year connection enactment tcja company require pay onetime transition tax company elect pay period year permit tcja note consolidated financial statement reflect payment collaborative agreement salesbase milestone achieve deem contractual obligation pay january note consolidated financial statement amount exclude reasonably certain lease renewal execute note consolidated financial statement table content purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount include contingent milestone payment relate collaborative arrangement acquisition consider contractual obligation successful achievement developmental regulatory approval commercial milestone december company recognize liability contingent salesbase milestone payment relate collaboration astrazeneca eisai bayer payment remain subject achievement relate sale milestone aggregate billion note consolidated financial statement exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million pension plan million international pension plan million postretirement benefit plan march company issue billion principal senior unsecured note consist million note billion note billion note billion note company net proceed offer billion general corporate purpose include repayment outstanding commercial paper borrowing december company exercise makewhole provision billion note repay debt november company launch tender offer certain outstanding note debenture company pay million aggregate consideration applicable purchase price accrue interest redeem million principal debt validly tender connection tender offer company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility march company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november mercks board director declare quarterly dividend share company outstanding common stock pay january january board director declare quarterly dividend share company common stock second quarter payable april october mercks board director authorize purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction company spend billion purchase million share common stock treasury addition company receive million share settlement asr agreement discuss december company remain share repurchase authorization billion company purchase billion billion common stock respectively authorize share repurchase program table content october company enter asr agreement thirdparty financial institution dealer asr agreement merck agree purchase billion merck common stock total initial delivery million share merck common stock base thencurrent market price dealer merck payment billion merck dealer october fund exist cash investment shortterm borrowing settlement asr agreement april merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program negotiate discount bring total share receive merck program million financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective company foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken table content currency exposure company december income taxis decline approximately million million respectively company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow economy argentina determine hyperinflationary consequently accordance gaap company begin remeasure monetary asset liability operation earning impact company result immaterial company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment comprehensive income loss oci remain accumulated comprehensive income loss aoci sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table million number interest rate total swap notional debt instrument par value debt swap hold note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value table content merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition disposition determine transaction account acquisition disposal asset business company make certain judgment include assessment input process output associate acquire set activity company determine substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition fair value intangible asset include acquire iprd determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probability weight cash flow subsequent acquisition date report period contingency resolve contingent consideration liability table content remeasure current fair value change expense income record earning change input result significantly different fair value adjustment judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate company determine transaction account acquisition business transaction account asset acquisition business combination goodwill record asset acquisition acquire iprd alternative future use charge expense contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment business company healthcare service segment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount united states sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year provision aggregate customer discount cover chargeback rebate chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge table content company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue company continually monitor provision aggregate customer discount material adjustment estimate associate aggregate customer discount provision summarize information change aggregate customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december outside united states variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale outside united states return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside united states payment term typically day day certain market long payment term distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce table content product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide abovementioned datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity table content assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension plan total million million million net periodic benefit credit postretirement benefit plan million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension plan largely attributable change discount rate affect net loss amortization company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum current market condition actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range decrease reflect low expect asset return modest shift asset allocation company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension table content postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize market relate value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design streamline company cost structure result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue termination cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect cost sale sell general administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price company conclude table content likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible asset exclude iprd initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize operating result judgment evaluate impairment longlive intangible materially affect company result operation impairment investment company review investment marketable debt security impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment marketable debt security include duration extent fair value cost change fair value consider temporary report net tax oci otherthantemporary impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit great likely table content realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement recently issue accounting standard discussion recently issue accounting standard note consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form q k item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck co inc subsidiary year end december millions share amount sale cost expense cost sale sell general administrative research development restructuring cost income expense net income taxis tax income net income net loss income attributable noncontrolle interest net income attributable merck co inc basic earning common share attributable merck co inc common shareholder earning common share assume dilution attributable merck co inc common shareholder consolidate statement comprehensive income merck co inc subsidiary year end december million net income attributable merck co inc comprehensive loss income net taxis net unrealized loss gain derivative net reclassification net unrealized gain loss investment net reclassification benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompany note integral consolidated financial statement table content consolidate balance sheet merck co inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck co inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck co inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck co inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck co inc comprehensive income net taxis cash dividend declare common stock share treasury stock share purchase acquisition valle sa net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc adoption new accounting standard comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net loss attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net loss attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge charge acquisition peloton therapeutics inc charge future payment relate collaboration license option provisional charge onetime transition tax relate enactment tax legislation defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment acquisition antelliq corporation net cash acquire acquisition peloton therapeutics inc net cash acquire acquisition net cash acquire net cash provide investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent restrict cash net increase decrease cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year include million restrict cash january include asset cash cash equivalent restrict cash end year include million restrict cash december include asset note accompany note integral consolidated financial statement table content note consolidated financial statement merck co inc subsidiarie million share amount nature operation merck co inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company recently sell certain business healthcare service segment process divest remain business alliance segment primarily include activity company relationship astrazeneca lp relate sale nexium prilosec conclude plan spinoff womens health legacy brand biosimilar new company february merck announce intention spinoff product womens health trust legacy brand biosimilar business new yettobename independent publicly trade company newco distribution newco publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose legacy brand include transaction consist dermatology pain respiratory select cardiovascular product include zetia vytorin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan newco development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete half subject market certain condition subsequent spinoff historical result woman health legacy brand biosimilar business reflect discontinued operation company consolidate financial statement summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis table content acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record asset acquisition acquire inprocess research development iprd alternative future use charge expense contingent consideration recognize acquisition date foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost net realizable value cost substantial majority pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt security classify availableforsale report fair value fair value company investment marketable debt security determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci company consider available evidence evaluate potential impairment investment marketable debt security include duration extent fair value cost thantemporary impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt security include income expense net investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net table content investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net revenue recognition january company adopt asu revenue contract customer subsequent amendment asc new guidance modify retrospective method comparative information prior period restate continue report accounting standard effect period recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allow company recognize revenue sale vaccine government stockpile sale meet criterion revenue recognition accounting guidance business company healthcare service segment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount united states sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year provision aggregate customer discount cover chargeback rebate billion billion billion chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue accrue balance relative provision chargeback rebate include account table content receivable accrue current liability million billion respectively december million billion respectively december outside united states variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product outside united states return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside united states payment term typically day day certain market long payment term depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion respectively software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development cost include property plant equipment addition company capitalize certain cost incur implement cloud computing arrangement consider service agreement include asset capitalize software cost amortize begin software project substantially complete asset ready intend use capitalize software cost associate project amortize year include company ongoing multi year implementation enterprisewide resource planning system million million net accumulate amortization december respectively capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible acquire intangible include product product right license trade name patent initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible table content recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result contingent consideration certain company acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale transaction account acquisition business fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning significant event increase decrease probability achieve development regulatory milestone increase decrease project cash flow result correspond increase decrease fair value relate contingent consideration obligation transaction account acquisition asset business contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve research development research development expense incur nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration research development expense include upfront milestone payment relate asset acquisition licensing transaction involve clinical development program receive regulatory approval collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner merck principal sale transaction party company recognize sale cost sale sell general administrative expense gross basis profit sharing amount pay collaborative partner record cost sale collaborative partner principal sale transaction party company record profit sharing amount receive collaborative partner alliance revenue sale alliance revenue record net cost sale include adjustment share commercialization cost partner accordance collaboration agreement adjustment determine compare commercialization cost merck incur directly report sell general administrative expense cost collaborative partner incur research development cost merck incur relate collaboration record research development expense cost reimbursement collaborative partner payment receive collaborative partner share cost pursuant term collaboration agreement record increase decrease research development expense table content addition term collaboration agreement require company payment base achievement certain developmental regulatory approval commercial milestone upfront milestone payment payable merck collaborative partner prior regulatory approval expense incur include research development expense payment collaborative partner subsequent regulatory approval capitalize amortize estimate useful life correspond intangible asset cost sale provide future cash flow support amount capitalize salesbased milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup probable achieve amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize cost sale remain useful life subject impairment testing sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income company account tax effect tax global intangible lowtaxed income gilti certain foreign subsidiary income tax provision period tax arise use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard february financial accounting standard board fasb issue new accounting guidance accounting reporting lease asu subsequently issue update new guidance asc new leasing guidance new leasing guidance require table content lessee recognize rightofuse asset lease liability lease lease meet definition shortterm lease lease classify operating finance operating lease result straightline expense income statement similar previous operating lease finance lease result expense recognize early year lease term similar previous capital lease company adopt new standard january modify retrospective approach merck elect transition method allow application standard adoption date begin early comparative period present financial statement company elect available practical expedient adoption company recognize billion additional asset relate liability consolidated balance sheet note adoption new leasing guidance impact company consolidate statement income cash flow april fasb issue new guidance accounting cost incur implement cloud computing arrangement consider service arrangement new guidance require capitalization cost align accounting cost associate develop obtain internaluse software company adopt new standard quarter prospective application eligible cost immaterial august fasb issue new guidance modifying disclosure requirement employer sponsor define benefit pension postretirement plan new guidance remove disclosure long consider cost beneficial clarifie specific requirement certain disclosure add disclosure requirement identify relevant company elect early adopt new guidance retrospective basis result minor change employee benefit plan disclosure note august fasb issue new guidance fair value measurement add remove modifie certain disclosure requirement company elect early adopt new guidance result minor change fair value disclosure note recently issue accounting standard adopt june fasb issue new guidance accounting credit loss financial instrument new guidance introduce expect loss model estimate credit loss replace incur loss model new guidance change impairment model availableforsale debt security require use allowance record estimate credit loss subsequent recovery company adopt new guidance effective january impact company consolidate financial statement adoption november fasb issue new guidance collaborative arrangement intend reduce diversity practice clarify certain transaction collaborative arrangement participant account revenue recognition guidance asc company adopt new guidance effective january result minor change footnote presentation information relate company collaborative arrangement december fasb issue amend guidance accounting reporting income taxis guidance intend simplify accounting income taxis remove exception relate certain intraperiod tax allocation defer tax liability clarify guidance primarily related evaluate stepup tax basis goodwill business combination reflect enact change tax law rate annual effective tax rate amend guidance effective interim annual period early adoption permit application amendment new guidance apply retrospective basis modify retrospective basis cumulativeeffect adjustment retain earning prospectively depend amendment company currently evaluate impact adoption consolidate financial statement january fasb issue new guidance intend clarify certain interaction accounting standard relate equity security equity method investment certain derivative guidance address accounting transition equity method accounting measure certain purchase option forward contract acquire investment new guidance effective interim annual period apply prospectively early adoption permit company currently evaluate impact adoption consolidate financial statement table content acquisition divestiture research collaboration license agreement company continue pursue acquisition business establishment external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share arrangement contingent occurrence certain future event link success asset development company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result recently complete transaction january merck acquire arqule inc arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease billion arqule lead investigational candidate mk arq novel oral bruton tyrosine kinase btk inhibitor currently phase dose expansion study treatment bcell malignancy company process determine preliminary fair value asset acquire liability assume total consideration transfer transaction account acquisition business transaction july merck acquire peloton therapeutics inc peloton clinicalstage biopharmaceutical company focus development novel small molecule therapeutic candidate target hypoxiainducible factor hif treatment patient cancer nononcology disease peloton lead candidate mk pt novel oral hif inhibitor latestage development renal cell carcinoma merck upfront payment billion cash additionally peloton shareholder eligible receive million regulatory approval million commercial sale united states billion salesbased milestone transaction account acquisition asset merck record cash million defer tax liability million net liability million acquisition date research development expense million relate transaction april merck acquire antelliq corporation antelliq leader digital animal identification traceability monitoring solution solution help veterinarian farmer pet owner gather critical datum improve management health wellbee livestock pet merck pay billion acquire outstanding share antelliq spend billion repay antelliqs debt transaction account acquisition business estimate fair value asset acquire liability assume antelliq follow million april cash cash equivalent account receivable inventory property plant equipment identifiable intangible asset useful life range year defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate primarily trade name determine income approach future net cash flow discount present value utilize discount rate actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate animal health segment goodwill deductible tax purpose table content company result include month activity antelliq company incur million transaction cost directly relate acquisition antelliq consist largely advisory fee reflect sell general administrative expense april merck acquire immune design latestage immunotherapy company employ nextgeneration vivo approach enable bodys immune system fight disease million cash transaction account acquisition business merck recognize intangible asset iprd million cash million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assume transaction company record aggregate charge million cost sale conjunction termination collaboration agreement enter samsung bioepis co ltd samsung insulin glargine charge reflect termination payment million represent reimbursement fee previously pay samsung merck agreement plus interest release merck ongoing obligation agreement charge include fix asset abandonment charge million inventory writeoff million relate cost million termination agreement impact company collaboration samsung june merck acquire viralytics limited viralytics australian publicly trade company focus oncolytic immunotherapy treatment range cancer aud million million transaction provide merck right v cva viralyticss investigational oncolytic immunotherapy v base viralyticss proprietary formulation oncolytic virus coxsackievirus type show preferentially infect kill cancer cell v currently evaluate multiple clinical trial intratumoral intravenous agent include combination keytruda previous agreement merck viralytic study investigate use keytruda v combination melanoma prostate lung bladder cancer transaction account acquisition asset merck record net asset million primarily cash acquisition date research development expense million relate transaction future contingent payment associate acquisition march merck eisai co ltd eisai enter strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discover eisai note transaction october merck acquire rigontec gmbh rigontec leader access retinoic acidinducible gene pathway innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity rigontec lead candidate mk rgt development treatment patient tumor term agreement merck upfront cash payment million million additional contingent payment million million relate achievement research milestone regulatory approval million relate achievement commercial target transaction account acquisition asset upfront payment reflect research development expense july merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer type note march merck acquire control interest valle sa valle lead privately hold producer animal health product brazil valle extensive portfolio product span parasiticide antiinfective vaccine include product livestock horse companion animal term agreement merck acquire share valle million total purchase price million place escrow pende resolution certain contingent item transaction account acquisition business merck recognize intangible asset million relate currently market product net defer tax liability million net asset million noncontrolle interest million addition company record liability million contingency identify acquisition date correspond table content indemnification asset million represent amount reimburse merck contingent liability pay excess consideration transfer fair value net asset acquire million record goodwill goodwill allocate animal health segment deductible tax purpose estimate fair value identifiable intangible asset relate currently market product determine income approach actual cash flow likely different assumed intangible asset relate currently market product amortize estimate useful life year fourth quarter merck acquire additional interest valle million reduce noncontrolle interest relate valle remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey remicade lose market exclusivity major european market company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck jj collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner party arrangement active participant expose significant risk reward dependent commercial success activity collaboration merck significant collaborative arrangement discuss astrazeneca july merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer type lynparza oral poly adpribose polymerase parp inhibitor currently approve certain type ovarian breast cancer company jointly develop commercialize lynparza monotherapy combination trial potential medicine independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicine keytruda imfinzi company jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek mitogenactivate protein kinase mapk pathway currently develop multiple indication term agreement astrazeneca merck share development commercialization cost lynparza selumetinib monotherapy nonpdlpd combination therapy opportunity gross profit lynparza selumetinib product sale generate monotherapie combination therapy share equally merck fund development commercialization cost keytruda combination lynparza selumetinib astrazeneca fund development commercialization cost imfinzi combination lynparza selumetinib astrazeneca principal lynparza sale transaction merck records share lynparza product sale net cost sale commercialization cost alliance revenue share development cost associate collaboration research development expense reimbursement receive astrazeneca research development expense recognize reduction research development cost agreement merck upfront payment astrazeneca billion payment million multiyear period certain license option million pay december million pay december million pay december company record aggregate charge billion research development expense relate upfront payment license option payment addition agreement provide additional contingent payment merck astrazeneca relate successful achievement salesbase regulatory milestone merck determine probable annual sale lynparza future trigger million salesbase milestone payment merck astrazeneca accordingly merck record table content million liability correspond increase intangible asset relate lynparza prior merck accrue salesbase milestone payment aggregate million million million pay astrazeneca respectively remainder million pay january potential future salesbase milestone payment billion accrue deem company probable time lynparza receive regulatory approval european union eu monotherapy treatment certain adult patient advance breast cancer monotherapy maintenance treatment certain adult patient brcamutate advanced ovarian cancer approval trigger million capitalize milestone payment merck astrazeneca lynparza receive regulatory approval trigger capitalize milestone payment million aggregate merck astrazeneca potential future regulatory milestone payment billion remain agreement intangible asset balance relate lynparza includes capitalize salesbased regulatory milestone payment million december include intangible net consolidated balance sheet amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue cost sale sell general administrative research development december receivables astrazeneca include current asset payable astrazeneca include accrue current liability payable astrazeneca include noncurrent liability represent amortization capitalize milestone payment include billion relate upfront payment license option payment include accrue milestone payment eisai march merck eisai announce strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discover eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination merck keytruda eisai record lenvima product sale globally eisai principal lenvima sale transaction merck eisai share gross profit equally merck record share lenvima product sale net cost sale commercialization cost alliance revenue expense incur codevelopment include study evaluate lenvima monotherapy share equally company reflect research development expense agreement merck upfront payment eisai million payment million certain option right million pay march million expect pay march million expect pay march company record aggregate charge billion research development expense relate upfront payment future option payment addition agreement provide additional contingent payment merck eisai relate successful achievement salesbase regulatory milestone merck determine probable annual sale lenvima future trigger salesbased milestone payment merck eisai aggregate million accordingly merck record million liability correspond increase intangible asset relate lenvima merck accrue salesbase milestone payment aggregate million relate lenvima amount million pay table content eisai additional million pay january potential future salesbase milestone payment billion accrue deem company probable time lenvima receive regulatory approval trigger capitalize milestone payment million aggregate merck eisai potential future regulatory milestone payment million remain agreement intangible asset balance relate lenvima includes capitalize salesbased regulatory milestone payment million december include intangible net consolidated balance sheet amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue cost sale sell general administrative research development december receivables eisai include current asset payable eisai include accrue current liability payable eisai include noncurrent liability represent amortization capitalize milestone payment include billion relate upfront payment option payment include accrue milestone future option payment bayer ag company enter worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas approve treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension company implement joint development commercialization strategy collaboration include clinical development bayer vericiguat phase trial worsen heart failure optin right earlystage sgc compound development bayer merck turn available earlystage sgc compound similar term agreement bayer lead commercialization adempas america merck lead commercialization rest world vericiguat potential optin product bayer lead commercialization rest world merck lead america product candidate include agreement company share development cost profit sale right copromote territory lead revenue adempas include sale merck marketing territory merck share profit sale adempas bayer marketing territory addition agreement provide additional contingent payment merck bayer relate successful achievement salesbase milestone merck determine probable annual worldwide sale adempas future trigger million salesbase milestone payment merck bayer accordingly merck record million liability correspond increase intangible asset related adempas company million milestone payment bayer accrued merck deem payment probable additional million potential future salesbase milestone payment accrue deem company probable time intangible asset balance relate adempas includes acquire intangible asset balance capitalize salesbased milestone payment million december include intangible net consolidated balance sheet amortize estimate useful life support project future cash flow subject impairment testing table content summarize financial information relate collaboration follow year end december net product sale record merck merck profit share sale bayer marketing territory total sale cost sale sell general administrative research development december receivables bayer include current asset payable bayer include noncurrent liability include amortization intangible asset represent accrue milestone payment restructure early merck approve new global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructure program include action associate plan spinoff newco company continue evaluate global footprint overall operating model subsequently identify additional action restructure program identify action time action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company estimate approximately cumulative pretax cost result cash outlay primarily relate employee separation expense facility shutdown cost approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect record charge approximately million related restructuring program action previous global restructuring program substantially complete company record total pretax cost million million million related restructuring program activity segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate cost depreciation total year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate accelerated depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck recording accelerate depreciation revise useful life site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include asset abandonment facility shutdown relate cost pretax gain loss result sale facility relate asset additionally activity include certain employeerelate cost associate pension postretirement benefit plan note sharebased compensation follow table summarize charge spend relate restructure program activity separation accelerate cost depreciation total restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december remain cash outlay expect substantially complete end table content financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year table content company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci effect company net investment hedge oci consolidated statement income show pretax gain loss recognize pretax gain loss recognize income expense net amount exclude comprehensive income effectiveness testing year end december net investment hedging relationship foreign exchange contract eurodenominate note amount reclassify aoci income relate sale subsidiary interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow table content table present location amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge december cumulative fair value hedge adjustment increase decrease include carrying hedge liability carry balance sheet line item hedge item include loan payable current portion longterm debt longterm debt present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract asset interest rate swap contract accrue current liability interest rate swap contract noncurrent liability foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument foreign exchange contract current asset foreign exchange contract accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross amount subject offset master netting arrangement offset consolidated balance sheet cash collateral receive net amount table content table provide information location pretax gain loss derivative designate fair value cash flow hedge relationship sale income expense net comprehensive income loss year end december financial statement line item effect fair value cash flow hedge record gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument impact cash flow hedging relationship foreign exchange contract gain loss recognize oci derivative decrease increase sale result aoci reclassification interest rate contract gain recognize income expense net derivative loss recognize oci derivative interest expense component income expense net table provide information income statement effect derivative designate hedge instrument derivative pretax gain loss recognize income year end december income statement caption derivative designate hedge instrument foreign exchange contract income expense net foreign exchange contract sale derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate derivative contract serve economic hedge forecast transaction december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealized amortize fair amortize fair cost gain loss value cost gain loss value commercial paper corporate note bond government agency security assetbacke security foreign government bond mortgagebacke security total debt security publicly trade equity security total debt publicly trade equity security unrealize net gain recognize income expense net equity security hold december million unrealize net loss recognize income expense net equity security hold december million december company million million respectively equity investment readily determinable fair value include asset company recognize unrealized gain million million respectively income expense net certain equity investment base favorable observable price change transaction involve similar investment investee addition company recognize unrealized loss million million respectively income expense net relate certain investment base unfavorable observable price change cumulative unrealized gain cumulative unrealized loss base observable price change investment equity investment readily determinable fair value million million respectively availableforsale debt security include shortterm investment total million december remain debt security million mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement level level level total level level level total asset investment commercial paper corporate note bond assetbacke security government agency security foreign government bond publicly trade equity security asset government agency security corporate note bond assetbacke security mortgagebacke security publicly trade equity security derivative asset forward exchange contract purchase currency option interest rate swap total asset liability liabilitie contingent consideration derivative liability forward exchange contract interest rate swap write currency option total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily auto loan credit card student loan receivables weightedaverage live primarily year investment include asset restrict use include payment benefit employee benefit plan fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy table content contingent consideration summarize information change liabilitie contingent consideration associate business acquisition follow fair value january change estimate fair value addition payment fair value december record cost sale research development expense income expense net include cumulative translation adjustment balance december include million record current liability amount expect pay month december million million respectively liability relate termination spmsd joint venture termination merck record liability contingent future royalty payment net sale merck product previously sell joint venture december fair value liability determine utilize estimate time project cash flow riskadjuste discount rate present value cash flow change estimate fair value liability contingent consideration largely attributable increase liability record connection termination sanofi pasteur msd spmsd joint venture increase partially offset reversal liability relate discontinuation program obtain connection acquisition smartcell note payment contingent consideration year relate spmsd termination liability describe payment contingent consideration include million relate achievement clinical development milestone mk gefapixant program obtain connection acquisition afferent pharmaceutical fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale united states europe china primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor global economic condition include volatility associate international sovereign economy associate impact financial market business company customer large account receivable balance mckesson corporation amerisourcebergen corporation cardinal health inc represent aggregate approximately total account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale company account receivable factoring agreement financial institution certain country sell account receivable company expand factoring arrangement china enter factoring agreement sell account receivable company major distributor company factor table content billion billion account receivable fourth quarter respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million behalf financial institution reflect restrict cash current asset relate obligation remit cash accrue current liability company remit cash financial institution january net cash flow relate collection report financing activity consolidate statement cash flow cost factor account receivable de minimis derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty cash collateral receive company counterpartie million million december respectively obligation return collateral record accrue current liability cash collateral advanced company counterpartie december inventory inventory december consist finished good raw material work process supply total approximate current cost decrease increase lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch table content goodwill intangible follow table summarize goodwill activity segment pharmaceutical animal health total balance january acquisition impairment balance december acquisition impairment balance december include cumulative translation adjustment goodwill balance certain adjustment accumulate goodwill impairment loss december million million respectively addition goodwill animal health segment primarily relate acquisition antelliq note impairment goodwill nonreportable segment relate certain business healthcare service segment intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right license iprd trade name acquire intangible include product product right license trade name patent initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life company significant acquire intangible net basis relate human health market product include product product right december include zerbaxa billion implanonnexplanon million gardasilgardasil million dificid million bridion million sivextro million simponi million additionally company billion acquire intangible related animal health market product december company significant intangible asset include license december include lenvima million lynparza million result collaboration eisai astrazeneca note increase trade name reflect billion intangible acquire antelliq acquisition note company intangible asset relate adempas result collaboration bayer note carry value million december reflect table company record impairment charge relate marketed product intangible million cost sale million relate sivextro product treatment acute bacterial skin skin structure infection cause designate susceptible grampositive organism reorganization reprioritization internal sale force company decision cease promotion sivextro market end decision result reduce cash flow projection sivextro indicate sivextro intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible table content asset relate sivextro compare related carrying value result impairment charge note company record impairment charge relate market product intangible million million relate intron treatment certain type cancer sale intron adversely affect availability new therapeutic option sale intron united states erode rapidly previously anticipate company lead change cash flow assumption intron revision cash flow indicate intron intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate intron compare related carrying value result impairment charge note remain charge relate impairment customer relationship tradename develop technology intangible certain business healthcare service segment iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization company record million iprd impairment charge research development expense million relate writeoff intangible asset balance program obtain connection acquisition iomet pharma ltd follow review clinical trial result conduct merck external clinical trial result similar compound discontinuation clinical development program result reversal relate liability contingent consideration million company record million iprd impairment charge million relate writeoff remain intangible asset balance program obtain connection smartcell acquisition follow decision terminate program product development issue discontinuation clinical development program result reversal relate liability contingent consideration million note company record million iprd impairment charge million result strategic decision discontinue development investigational combination regimen mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hepatitis c virus hcv infection decision base review available phase efficacy datum consideration evolve marketplace grow number treatment option available patient chronic hcv infection include zepati market company treatment adult patient chronic hcv infection result decision company record iprd impairment charge writeoff remain intangible asset relate uprifosbuvir iprd impairment charge include charge million writeoff intangible asset relate verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleave enzyme bace result decision february stop phase study evaluate verubecestat people prodromal alzheimer disease decision stop study follow recommendation external datum monitor committee edmc assess overall benefitrisk interim safety analysis edmc conclude unlikely positive benefitrisk establish trial continue iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense record cost sale billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion table content loan payable longterm debt lease loan payable loan payable december include billion note billion commercial paper million longdate note subject repayment option holder loan payable december include billion commercial paper million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively longterm debt longterm debt december consist note note note note note note note note eurodenominate note eurodenominate note note note note note eurodenominate note eurodenominate note eurodenominate note note note note debenture note debenture debenture note floatingrate note present table include million million december respectively borrowing variable rate result effective interest rate respectively exception debenture note list table redeemable merck option time vary redemption price march company issue billion principal senior unsecured note consist million note billion note billion note billion note company net proceed offer billion general corporate purpose include repayment outstanding commercial paper borrowing table content effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply covenant december company compliance covenant aggregate maturity longterm debt year follow billion billion billion billion billion company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility lease discuss note january merck adopt new guidance accounting reporting lease company operating lease primarily manufacture facility research development facility corporate office employee housing vehicle certain equipment permit transition guidance asc company elect package practical expedient provision allow company carry forward historical lease classification company determine arrangement lease inception evaluate contract embed lease company exercise judgment determine explicit implicit identify asset contract merck control use asset embed lease primarily associate contract manufacturing organization immaterial asc transition guidance merck elect hindsight practical expedient determine lease term exist lease permit company consider available information prior effective date new guidance actual likely exercise option extend terminate lease lease term include option extend terminate lease reasonably certain merck exercise option real estate lease facility average remain lease term year include option extend lease year applicable vehicle lease generally effect year company accounting policy election record shortterm lease lease initial term month balance sheet merck currently shortterm lease lease expense operating lease payment recognize straightline basis term lease operating lease asset liability recognize base present value lease payment lease term company lease readily determinable implicit discount rate company use incremental borrowing rate calculate present value lease payment asset class quarterly basis update incremental borrowing rate determine base average remain lease term asset class company pretax cost debt term update rate asset class apply prospectively new lease practical expedient company accounting policy election asset class separate lease component eg payment rent real estate taxis insurance cost nonlease component eg commonarea maintenance cost event agreement contain merck include lease nonlease component purpose calculate rightofuse asset relate lease liability nonlease component fix vehicle lease employee housing company apply portfolio approach effectively account operating lease asset liability certain company lease agreement contain variable lease payment adjust periodically inflation actual operating expense true up compare estimate amount amount immaterial sublease income activity relate sale leaseback transaction immaterial merck lease agreement contain material residual value guarantee material restrictive covenant operate lease cost million cash pay amount include measurement operating lease liability million operating lease asset obtain exchange lease obligation million table content supplemental balance sheet information relate operating lease follow december asset asset liability accrue current liability noncurrent liability weightedaverage remain lease term year weightedaverage discount rate include prepaid lease relate lease liability maturity operating lease liability follow total lease payment imputed interest december company enter additional real estate operating lease commence obligation associate lease total million million relate lease commence april lease term year december prior adoption asc minimum aggregate rental commitment noncancellable lease follow million million million million million million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter opinion company unlikely resolution matter material company financial condition result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice ii extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation iv settlement posture party litigation v factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable table content company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case pende merck federal state court plaintiff vast majority case generally allege sustained femur fracture andor bone injury femur fracture association use fosamax federal case involve allegation femur fracture transfer multidistrict litigation district new jersey femur fracture mdl bellwether case try date femur fracture mdl glynn v merck jury return verdict merck favor addition june femur fracture mdl court grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law august femur fracture mdl court enter order require plaintiff femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case pursuant cause order march femur fracture mdl court dismiss prejudice approximately case preemption ground plaintiff approximately case appeal decision court appeal circuit circuit march circuit issue decision reverse femur fracture mdl court preemption ruling remand appeal case femur fracture mdl court merck file petition writ certiorari supreme court august seek review circuit decision supreme court grant merck petition june supreme court issue opinion decide circuit incorrectly conclude issue preemption resolve jury accordingly vacate judgment circuit remand proceeding circuit address issue manner consistent supreme courts opinion november circuit remand case district court order allow court determine instance plaintiff state law claim preempt federal law standard describe supreme court opinion december district court order merck serve open brief february plaintiff file responsive brief april merck file reply accordingly december approximately case actively pende femur fracture mdl december approximately case allege femur fracture file new jersey state court pending judge james hyland middlesex county party select initial group case review fact discovery merck continue select additional case review december approximately case allege femur fracture file pende california state court femur fracture case file california state court coordinate single judge orange county california additionally femur fracture case pende state court discovery presently stay femur fracture mdl state court california merck intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december merck aware approximately product user allege januvia andor janumet cause development pancreatic cancer injury table content claim file multidistrict litigation district court southern district california mdl outside mdl majority claim file coordinated proceeding superior court california county los angeles california state court november mdl california state courtin separate opinionsgrante summary judgment defendant ground federal preemption plaintiff appeal forum november court appeals ninth circuit vacate judgment remand discovery november california state appellate court reverse remand similar ground march party mdl california coordinated proceeding agree coordinate adopt schedule completing discovery general causation preemption issue renew summary judgment daubert motion stipulate case management schedule hearing daubert summary judgment motion expect place june december product user claim pende merck state court california include illinois june illinois trial court deny merck motion summary judgment base federal preemption merck appeal illinois appellate court affirm december merck file petition leave appeal illinois supreme court february april illinois supreme court stay consideration pende petition appeal supreme court issue opinion merck sharp dohme corp v albrecht relate fosamax matter discuss merck file opinion albrecht illinois supreme court june petition leave appeal decide september illinois supreme court direct intermediate appellate court reconsider early rule illinois appellate court issue favorable decision conclude consistent albrecht preemption present legal question resolve court addition claim note company agree toll statute limitation approximately additional claim company intend continue defend lawsuit vioxx previously disclose merck defendant lawsuit bring attorney general utah allege merck misrepresented safety vioxx lawsuit pende utah state court utah seek damage penalty utah false claim act bench trial matter currently schedule april governmental proceeding previously disclose fall company receive record subpoena attorney office district vermont vt usao pursuant section health insurance portability accountability act hipaa relate investigation potential health care offense subpoena seek information relate actual potential business relationship arrangement merck practice fusion inc pfi cloudbase electronic health record ehr company acquire allscripts january company cooperate government respond subpoena subsequently merck receive second record subpoena vt usao broaden government information request seek information relate merck relationship ehr company shortly vt usao serve civil investigation demand cid merck similarly seek information company relationship ehr vendor cid explain government conduct false claim act investigation concern merck andor pfi submit claim federal healthcare program violate federal antikickback statute merck cooperate government investigation previously disclose april merck receive set investigative interrogatory california attorney general office pursuant investigation conduct agreement allegedly affect delay competition lantus insulin market interrogatory seek information concern merck development insulin glargine product subsequent termination merck patent litigation sanofi sa concern lantus resolution litigation merck cooperate california attorney general investigation previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry table content relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate previously disclose time time company receive inquiry subject preliminary investigation activity competition governmental authority market outside united states authority include regulator administrative authority law enforcement similar official preliminary investigation activity include site visit formal informal request demand document material inquiry interview similar matter certain preliminary inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require commercial litigation zetia antitrust litigation previously disclose merck msd schering corporation msp singapore company llc collectively merck defendant defendant putative class action optout lawsuit file behalf direct indirect purchaser zetia allege violation federal state antitrust law state statutory common law cause action case consolidated pretrial purpose federal multidistrict litigation judge rebecca beach smith eastern district virginia december court deny merck defendant motion dismiss stay direct purchaser putative class action pende bilateral arbitration august district court adopt report recommendation magistrate judge respect merck defendant motion dismiss nonarbitration issue grant deny merck defendant motion dismiss addition june representative putative direct purchaser class file amend complaint august retailer optout plaintiff file amend complaint merck defendant move dismiss new allegation complaint october magistrate judge issue report recommendation recommend district judge grant motion entirety december district court adopt report recommendation district court grant merck defendant motion dismiss extent motion seek dismissal claim overcharge pay entity purchase generic ezetimibe par pharmaceutical inc par pharmaceutical dismiss claim overcharge trial currently schedule begin october rotavirus vaccine antitrust litigation previously disclose msd defendant putative class action lawsuit file behalf direct purchaser rotateq allege violation federal antitrust law case consolidate eastern district pennsylvania january court deny msds motion compel arbitration dismiss consolidate complaint february msd appeal court order arbitration circuit october circuit vacate district court order remand limited discovery issue arbitrability msd file renew motion compel arbitration sale force litigation previously disclose ms kelli smith file complaint company district court district new jersey behalf putative class female sale representative putative subclass female sale representative child claim discriminatory policy practice selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination law april magistrate judge grant plaintiff request amend complaint add follow company subsidiary corporate defendant ii erisa claim iii individual constructive discharge claim name plaintiff approximately individual optedin action optin period close august plaintiff file motion certify title vii pay discrimination class seek final collective action certification plaintiff equal pay act claim october party enter agreement fully resolve smith sale force litigation settlement exchange general release individual class claim company agree pay million december court approve settlement table content qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr ii vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr ii vaccine charge company misrepresent efficacy mmr ii vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery complete party file brief cross motion summary judgment currently pende court company continue defend lawsuit merck kgaa litigation previously disclose january protect longestablished brand rights united states company file lawsuit merck kgaa darmstadt germany kgaa historically operate emd group united states allege improperly use merck united states kgaa file suit company france uk germany switzerland mexico india australia singapore hong kong china allege thing unfair competition trademark infringement andor corporate infringement uk australia singapore hong kong india kgaa allege breach party coexistence agreement litigation ongoing united states trial date set ongoing numerous jurisdiction outside united states company defend suit jurisdiction patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application nda food drug administration fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition potentially significant intangible asset impairment charge januvia janumet janumet xr february par pharmaceutical file suit company district court district new jersey seek declaratory judgment invalidity patent own company cover certain salt polymorphic form sitagliptin expire response company file patent infringement lawsuit district court district delaware par pharmaceutical additional company indicate intent market generic version januvia janumet janumet xr follow expiration key patent protection prior expiration latergrante patent own company cover certain salt polymorphic form sitagliptin expires later grant patent own company cover janumet formulation expire par pharmaceutical dismiss case district court district new jersey company litigate action district court district delaware company file patent infringement lawsuit mylan pharmaceuticals inc mylan inc mylan northern district west virginia judicial panel multidistrict litigation enter order transfer company lawsuit mylan district court district delaware coordinate consolidated pretrial proceeding case pende district district court district delaware schedule lawsuit single day trial invalidity issue october court schedule separate day trial infringement issue necessary october mylan file petition inter parte review ipr united states patent trademark office table content uspto seek invalidity patent uspto month filing determine institute request ipr proceeding litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial condition result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial condition result operation liquidity company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year table content equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan october company enter accelerated share repurchase asr agreement thirdparty financial institution dealer asr agreement merck agree purchase billion merck common stock total initial delivery million share merck common stock base thencurrent market price dealer merck payment billion merck dealer october fund exist cash investment shortterm borrowing payment dealer record reduction shareholder equity consist billion increase treasury stock reflect value initial million share receive october billion decrease otherpaidin capital reflect value stock hold dealer pende final settlement settlement asr agreement april merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program negotiate discount bring total share receive merck program million sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period subject term applicable award psu award generally vest year prior rsu award generally vest year begin award grant rsu award generally vest onethird year threeyear period total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively table content company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree interest rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december table content december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plan consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset amortization unrecognize prior service cost net loss amortization termination benefit curtailment settlement net periodic benefit cost credit change net periodic benefit cost credit year year pension plan largely attributable change discount rate affect net loss amortization connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan settlement record certain international pension plan reflect table component net periodic benefit cost credit service cost component include income expense net note exception certain amount termination benefit curtailment settlement record restructuring cost event give rise termination benefit curtailment settlement related restructuring action note table content obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability actuarial loss gain primarily reflect change discount rate december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately respectively company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment plan asset fair value international pension plan asset cash cash equivalent investment fund develop market equity government agency obligation emerge market equities corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plans level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return table content target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution expect contribution approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost credit arise period net loss amortization include benefit cost prior service credit amortization include benefit cost table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate interest credit rate benefit obligation discount rate salary growth rate interest credit rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis expect rate return plan develop consider longterm historical return data current market condition actual return plan asset reference information longterm return expectation asset category weightedaverage expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range decrease reflect low expect asset return modest shift asset allocation change weightedaverage expect return pension postretirement benefit plan asset relative weighting reference plan asset health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss gain income investment equity security net net periodic define benefit plan credit cost service cost net include net realize unrealized gain loss investment equity security own directly ownership interest investment fund net present table include million goodwill impairment charge relate certain business healthcare service segment note net include gain million relate settlement certain patent litigation income million relate astrazenecas option exercise connection termination company relationship astrazeneca lp azlp gain million result receipt milestone payment outlicense migraine clinical development program net include million goodwill impairment charge relate certain business healthcare service segment note million charge relate writedown asset hold sale fair value anticipation dissolution company joint venture supera farma laboratorio sa brazil net include income million relate astrazenecas option exercise million loss extinguishment debt interest pay million million million taxis income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning gilti foreignderive intangible income deduction tax settlement rd tax credit state taxis acquisition peloton tcja valuation allowance acquisitionrelate cost include amortization restructuring include tax effect loss foreign subsidiary miscellaneous item table content tax cut job act tcja enact december provision tcja reduce federal corporate statutory tax rate effective january require company pay onetime transition tax undistribute earning certain foreign subsidiary create new taxis certain foreign sourced earning company reflect impact tcja financial statement application certain provision tcja remain subject interpretation certain instance company reasonable estimate effect tcja finalize describe onetime transition tax base company post undistribute earning profit ep substantial portion undistribute ep company previously provide defer taxis earning deem merck retain indefinitely subsidiary company reinvestment company record provisional onetime transition tax liability billion provisional reduce reversal billion defer taxis previously record connection merger scheringplough corporation certain undistributed foreign ep basis revise calculation post undistribute foreign ep finalization amount hold cash specify asset company recognize measurementperiod adjustment million relate transition tax obligation correspond adjustment income tax expense period result revise transition tax obligation billion company record additional charge million relate finalization treasury regulation associated tcja permit tcja company elect pay onetime transition tax period year company remain transition tax liability reduce payment utilization foreign tax credit billion december million include income taxis payable remainder billion include noncurrent liability company remeasure defer tax asset liability new federal statutory tax rate result provisional defer tax benefit million basis clarification defer tax benefit calculation company record measurementperiod adjustment million relate deferred income taxis foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate united states particularly ireland switzerland singapore puerto rico operate tax incentive grant begin expire earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact intangible asset impairment charge amortization purchase accounting adjustment restructure cost item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability product intangible license inventory relate accelerated depreciation pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer taxis nol carryforward relate foreign jurisdiction valuation allowance billion establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs discuss include million relate divestiture merck consumer care business table content company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease approximately million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount benefit expense million million million amount reflect beneficial impact tax settlement include discuss liability accrue interest penalty million million december respectively internal revenue service irs conclude examination merck federal income tax return result company require payment million company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit net benefit reflect reduction reserve unrecognize tax benefit tax position relate year examination partially offset additional reserve tax position previously reserve irs conclude examination merck federal income tax return result company require payment approximately billion company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record net million tax benefit net benefit reflect reduction reserve unrecognize tax benefit tax position relate year examination partially offset additional reserve tax position previously reserve adjustment reserve unrecognize tax benefit relate year remain open examination affect settlement irs currently conduct examination company tax return year addition state foreign tax examination progress jurisdiction company income tax return open examination period earning share calculation earning share share millions follow year end december net income attributable merck co inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck co inc common shareholder earning common share assume dilution attributable merck co inc common shareholder issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis adoption asu adoption asu balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain loss sale availableforsale investment reclassify aoci income expense net amount include investment debt equity security result adoption asu amount relate investment availableforsale debt security include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile result change companys internal reporting structure certain cost previously include pharmaceutical segment include nonsegment expense merck research laboratory prior period pharmaceutical segment profit recast reflect change comparable basis animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company recently sell certain business healthcare service segment process divest remain business alliance segment primarily include activity company relationship astrazeneca lp relate sale nexium prilosec conclude table content sale company product follow year end december intl total intl total intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima emend vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion noxafil primaxin invanz cubicin cancidas immunology simponi remicade neuroscience belsomra virology isentressisentress hd zepatier cardiovascular zetia vytorin atozet adempas diabete januvia janumet womens health nuvare implanonnexplanon diversify brand singulair cozaarhyzaar nasonex arcoxia follistim aq pharmaceutical total pharmaceutical segment sale animal health livestock companion animal total animal health segment sale segment sale total segment sale plus international equal total round alliance revenue represent merck share profit product sale net cost sale commercialization cost note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment healthcare service alliance primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale include approximately million million million respectively relate sale marketing right certain product table content consolidated sale geographic area derive follow year end december united states europe middle east africa japan china asia pacific japan china latin america reconciliation segment profit income taxis follow year end december segment profit pharmaceutical segment animal health segment segment total segment profit profit unallocate interest income interest expense depreciation amortization research development amortization purchase accounting adjustment restructure cost charge relate termination collaboration samsung loss extinguishment debt unallocated net income taxis pharmaceutical segment profit comprise segment sale standard cost sell general administrative expense directly incur segment animal health segment profit comprise segment sale cost sale sell general administrative expense research development cost directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur merck research laboratory companys research development division focus human healthrelated activity general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacturing sale unallocate net include expense corporate manufacturing cost center goodwill intangible asset impairment charge gain loss sale business expense income relate change estimate fair value liability contingent consideration miscellaneous income expense item table content equity income loss affiliate depreciation amortization include segment profit follow pharmaceutical animal health total year end december include segment profit equity income loss affiliate depreciation amortization year end december include segment profit equity income loss affiliate depreciation amortization year end december include segment profit equity income loss affiliate depreciation amortization property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific japan china latin america china japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director stockholders merck co inc opinion financial statement internal control financial reporting audit accompany consolidated balance sheet merck co inc subsidiary company december relate consolidated statement income comprehensive income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report internal control financial reporting appear item responsibility express opinion company consolidate financial statement companys internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable table content assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement ii involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate customer discount accrual medicaid manage care medicare rebate describe note consolidated financial statement company record certain variable consideration include discount estimate time sale generally expect value method amount accrue aggregate customer discount december billion evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue certain discount form rebate amount owe base definitive contractual agreement legal requirement private sector manage care public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider management use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision principal consideration determination perform procedure relate customer discount accrual medicaid manage care medicare rebate critical audit matter significant judgment require management significant measurement uncertainty calculation rebate accrual include assumption relate price customer segment utilization pertain forecast customer claim fully pay subsequent period turn lead high degree auditor judgment subjectivity effort apply procedure relate assumption address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate customer discount accrual medicaid manage care medicare rebate include management control assumption estimate correspond rebate accrual procedure include develop independent estimate rebate accrual utilize party datum customer segment utilization change price term specific rebate program historical trend actual rebate claim pay independent estimate compare rebate accrual record management evaluate reasonableness estimate additionally procedure include test actual rebate claim pay evaluate contractual term company rebate agreement pricewaterhousecooper llp florham park new jersey february serve company auditor table content b supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount th q rd q nd q st q sale cost sale sell general administrative research development restructuring cost income expense net income taxis net income attributable merck co inc basic earning common share attributable merck co inc common shareholder earning common share assume dilution attributable merck co inc common shareholder sale cost sale sell general administrative research development restructuring cost income expense net income taxis net income attributable merck co inc basic earning common share attributable merck co inc common shareholder earning common share assume dilution attributable merck co inc common shareholder amount include charge relate acquisition peloton therapeutics inc note amount include charge relate formation collaboration eisai note amount reflect acquisition divestiturerelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule ae de securities exchange act amend act effective fourth quarter change internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue table content committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth c frazier robert davis chairman president executive vice president global services chief executive officer chief financial officer item b information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section securities exchange act applicable incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website httpwwwmsdcomabouthowwe operatecodeofconductvaluesandstandardshtml company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation benefit committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck co inc incentive stock plan merck co inc nonemployee directors stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck co inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content iv item